

Dyslipidemia: Genetics and Role in the Metabolic Syndrome

Nora L. Nock and Aiswarya L.P. Chandran Pillai
*Case Western Reserve University
USA*

1. Introduction

Dyslipidemia is characterized by an aggregation of lipoprotein abnormalities including low high density lipoprotein cholesterol (HDL-C), high serum triglycerides (TG) and increased small low density lipoprotein cholesterol (LDL-C). Lipoproteins, which contain lipids and proteins (apolipoproteins, APO) are responsible, primarily, for transporting water insoluble lipids (cholesterol, TG) in plasma from the intestines and liver, where they are absorbed and synthesized, respectively, to peripheral tissues (muscle, adipose) for utilization, processing and/or storage (Kwan et al., 2007). There are several subtypes of lipoproteins with specific functions including, from smallest to largest: 1) chylomicrons, which transport dietary TG from the intestines to the peripheral tissue and liver; 2) very LDL (VLDL) particles, which transport TG from the liver to peripheral tissues; 3) intermediate density lipoproteins (IDL), which are produced from VLDL particle metabolism and may be taken up by the liver or further hydrolyzed to LDL; and, 4) HDL, which is key in 'reverse cholesterol transport' or shuttling cholesterol from peripheral cells to the liver (Kwan et al., 2007).

The Metabolic Syndrome (MetSyn) is a clustering of traits including dyslipidemia as well as hypertension (raised systolic and/or diastolic blood pressure), dysglycemia (high fasting glucose) and obesity (high body mass index (BMI) and/or waist circumference). Dyslipidemia is formally defined within the context of MetSyn. Various diagnostic definitions have been proposed for MetSyn by several organizations including the World Health Organization (WHO) (Alberti and Zimmet, 1998), European Group Insulin Resistance (EGIR) (Balkau and Charles, 1999), National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III, (2001), International Diabetes Federation (IDF, (Alberti et al., 2005), American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI) (Grundy et al., 2006) and, with the most recent joint interim statement proposed by the AHA/NHLBI, IDF and other organizations (Alberti et al., 2009). Although the recommendations differ widely on the obesity component, the dyslipidemia component has been fairly consistently defined as having TG ≥ 150 mg/l, HDL-C <40 mg/dL (1.03 mmol/l, in males) or <50 mg/dL (1.29 mmol/l in females) or drug treatment for elevated TG or low HDL-C (NCEP ATP III: (2001), IDF: (Alberti et al., 2005), Joint Statement: (Alberti et al., 2009)). However, the WHO (Alberti and Zimmet, 1998) proposed slightly lower limits for HDL-C (male: <0.9 mmol/l (35 mg/dl); female: <1.0 mmol/l (39 mg/dl)) and the EGIR (Balkau and Charles, 1999) recommended dyslipidemia be defined by HDL-C <1.0 mmol/l (39 mg/dl) or TG >2.0 mmol/l (177 mg/dl). There is currently no recommended value for

LDL-C levels in the context of MetSyn yet LDL-C remains the primary target of therapy for the management of high blood cholesterol per the most recent guidelines from the NCEP ATP III, which recommended drug therapy for LDL-C values ranging from ≥ 100 mg/dl to ≥ 190 mg/dl depending on the presence/absence of other coronary heart disease (CHD) risk factors (Grundey et al., 2004). When LDL becomes lipid depleted, small dense LDL (sdLDL) particles are formed, which have a lower affinity for the LDL receptor (LDLR), more susceptibility to oxidation and a higher affinity for macrophages; and, thus, sdLDL particles contribute to the atherosclerotic process (Austin et al., 1990; Littlewood and Bennett, 2003) and likely MetSyn (Kruit et al., 2010).

Dyslipidemia and MetSyn are common in developed nations and the prevalence of both are rising worldwide, which may be attributed, in part, to the rising rates of overweight and obesity (Alberti et al., 2009; Halpern et al., 2010). According to the National Health and Nutrition Examination Survey (NHANES) III (1988-1994) in the United States (U.S.), which used the NCEP ATP III criteria, the age-adjusted prevalence of dyslipidemia defined by high TG or low HDL-C, was approximately 30.0% and 37.1%, respectively; and, the prevalence of MetSyn was approximately 23.7% (Ford et al., 2002). The prevalence of dyslipidemia and MetSyn generally increase with increasing age (Ford et al., 2002). However, in a more recent study that used the Health Survey for England (HSE) (2003-2006) survey data and NHANES (1999-2006) data with exclusion of persons over 80 years old, the prevalence of low HDL-C (defined in both males and females as < 40 mg/dL) was 10.0% in England and 19.2% in the U.S. (Martinson et al., 2010). Thus, the prevalence can vary markedly depending on how these traits are defined (Cook et al., 2008). Interestingly, trends in the U.S. and England indicate during the past two decades an increase in the proportion of individuals diagnosed with high cholesterol (≥ 240 mg/dL) but who achieved therapeutic control (Roth et al., 2010). For example, in the U.S. in 2006, 54.0% of men (95% CI: 47.6-60.4) and 49.7% of women (95% CI: 44.3-55.0) with high total serum cholesterol were on cholesterol-lowering medication, as opposed to 10.8% of men (95% CI: 8.0-13.6) and 8.6% (95% CI: 6.7-10.6) of women in 1993 (Roth et al., 2010). In England, in 2006, 35.5% of men (95% CI: 32.8-38.3) and 25.7% of women (95% CI: 23.4-28.1) were on cholesterol-lowering medication as opposed to 0.6% of men (95% CI: 0.3-1.3) and 0.4% of women (95% CI: 0.1-0.7%) in 1993 (Roth et al., 2010). Thus, prevalence rates will also vary by whether or not relevant drug treatments have been considered and, perhaps, the list of relevant drugs should include cholesterol lowering therapies (e.g., statins) as well as other drugs (e.g., tamoxifen, glucocorticoids) known to alter TG and cholesterol levels (Garg and Simha, 2007).

Both dyslipidemia and MetSyn increase the risk of Type II diabetes mellitus (T2DM) (Adiels et al., 2006; Kruit et al., 2010) and cardiovascular disease (CVD) morbidity (Alberti et al., 2009; Linsel-Nitschke and Tall, 2005) and CVD mortality (Lewington et al., 2007). Patients with MetSyn have a five-fold increase in the risk of developing T2DM and are at twice the risk of developing CVD over the next 5 to 10 years compared to individuals without the syndrome (Alberti et al., 2009). In the presence of both MetSyn and T2DM, the prevalence of CVD is markedly increased with an odds ratio (OR) of 3.04 [95% confidence interval (CI) of OR: 1.98-4.11] in comparison to those with none of these conditions (Athysos et al., 2004). The importance of MetSyn is exemplified by its ICD-9 code (277.7), which was initially established as a diagnosis of "Dysmetabolic Syndrome X" (Einhorn et al., 2003; Kahn et al., 2005). In summary, both dyslipidemia and MetSyn are substantial public health problems, which require a better understanding of their respective etiologies to develop more effective lifestyle and therapeutic interventions.

Heritability estimates suggest there is a strong genetic component to dyslipidemia and MetSyn. Heritability estimates for dyslipidemia range from 0.20 to 0.60 (Edwards et al., 1997; Goode et al., 2007; Herbeth et al., 2010; Kronenberg et al., 2002; Wang and Paigen, 2005) and from 0.24 to 0.63 for MetSyn (Lin et al., 2005; Sung et al., 2009).

Multiple genetic variants in the form of single nucleotide polymorphisms (SNPs) (i.e., single DNA base changes) have been associated with manifestation of dyslipidemia and MetSyn. In this chapter, we review and summarize associations between common SNPs (i.e., those with a minor allele frequency (MAF) ≥ 0.05) in the most biologically plausible candidate genes and HDL-C, LDL-C and TG levels as well as MetSyn as a single, unifying trait. Previous estimates suggest all common variants together explain less than 10 percent of HDL-C levels in the general population (Kronenberg et al., 2002); however, more elegant statistical modeling methods that combine SNPs in a more biologically meaningful way may be needed to better understand the collective role of genetic variants in manifestation of dyslipidemia, MetSyn and other complex metabolic traits. As a result, at the end of this chapter, we review studies that have undertaken more complex modeling strategies to understand the aggregate effects of SNPs in manifestation of dyslipidemia and MetSyn and provide our insights for future directions in this field.

2. Genetic variants in lipid metabolism and HDL-C levels

As mentioned above, HDL-C is important for “reverse cholesterol transport” or the shuttling of cholesterol from peripheral cells to the liver. Many of the genetic variants associated with HDL-C levels have been summarized nicely in a recent comprehensive review by Boes et al. (Boes et al., 2009). In Table 1, we include common SNPs tabulated in Boes et al. (2009) review of large studies (ethnic group sample sizes ≥ 500) as well as common SNPs in large studies that have been identified since their review.

Gene	Polym.	rs Number	MAF	Ethn.	Sample Size	Results (Effect Size, p-value)	Reference
ABCA1	C (-297)T	rs2246298	0.25 (T)	A	1625 (GP)	p=0.0455	(Shioji et al. 2004b)
ABCA1	G (-273)C	rs1800976	0.40 (C)	A	1626 (GP) 735 (HBP)	+1.9/+2.7 mg/dl (1/2copies); p=0.03 +1.9 /+5.0 mg/dl (1/2 copies); p=0.03	(Shioji et al. 2004b)
ABCA1	G (-273)C	rs1800976	0.38 (T)	Tu	2332 (GP)	+0.7/+1.9 mg/dl (1/2 copies); p<0.02	(Hodoglugil et al. 2005)
ABCA1	G378C	rs1800978	0.13 (C)	W	5040 (GP)	-1.2/- 2.7 mg/dl (1/2 copies); p=0.03	(Porchay et al. 2006)
ABCA1		rs3890182	0.13 (A)	W	5287 (GP)	-1/-3 mg/dl (1/2 copies) ; p=0.003	(Kathiresan et al. 2008)
ABCA1		rs2275542		A	<1880 (GP)	p=0.006	(Shioji et al. 2004b)

ABCA1		rs2515602	0.27	B	1943 (P)	M; p=0.034; F; p<0.001	(Klos et al. 2006a)
ABCA1	G596A	rs2853578	0.28 (A)	W	2468 CVD 834 (Co)	0.2 / +2.8 mg/dl (1/2 copies); p=0.02	(Whiting et al. 2005)
ABCA1	2310G>A	rs2066718	0.03 (A)	W	9123 (P)	F: higher levels in carriers; p=0.02	(Frikke-Schmidt et al. 2004)
ABCA1	G2706A	rs2066718	0.05 (A)	Tu	2458 (GP)	M: +2.0 mg/dl for heterozygotes; p<0.01	(Hodoglugil et al. 2005)
ABCA1	2472G>A G2868A	rs2066718	0.06 (A)	Tu	2105 (GP)	F: +3.1 mg/dl for carriers; p=0.0005	(Hodoglugil et al. 2005)
ABCA1	1883M	rs4149313	0.12 (G)	W	9123 (P)	F: + heterozygotes; p=0.05	(Frikke-Schmidt et al. 2004)
ABCA1	32b.+30, ABC32			W	1543 (P)	-2.2 mg/dl for carriers ; p=0.0040	(Costanza et al. 2005)
ABCA1	R1587K	rs2230808	0.24 (A)	W	9123 (P)	M: - 1.5 mg/dl for heterozygotes; p=0.008	(Frikke-Schmidt et al. 2004)
ABCA1	4759G > A	rs2230808	0.26 (K)	W	779 (CVD)	-1.5 mg/dl for carriers; p=0.03	(Clee et al. 2001)
ABCA1	50b.3038, ABC50	rs41474449	.	W	1543 (P)	+1.6 mg/dl for carriers; p=0.043	(Costanza et al. 2005)
ABCA1		rs3890182	0.12 (A)	EA	25,167	p= 4.53E-07	(Dumitrescu et al. 2011)
APOA1	T84C (HaeIII)	rs5070	0.23 (C)	A	1637 (GP)	+1.9 / +5.4 mg/dl (1/2copies); p=0.0005	(Shioji et al. 2004a)
APOA1	MspI RFLP	rs5069	0.31 (C)	B	3831 (P)	M/F; p=n.s./0.022	(Brown et al. 2006)
APOA1		rs28927680	0.93 (G)	EA	25,167	p= 8.61E-09	(Dumitrescu et al. 2011)
APOA1		rs964184	0.86 (C)	EA	25,167	p= 6.08E-10	(Dumitrescu et al. 2011)
APOA5	- 1131T > C	rs662799	0.06 (C)	UK	1696 (P)	-1.5 mg/dl / -5.4 mg/dl (1/2 copies) ; p=0.04	(Talmud et al. 2002a)
APOA5	- 1131T > C	rs662799	0.07 (C)	W	1596(SA PHIR)	-3.5 mg/dl per copy; p=0.00038	(Grallert et al. 2007)
APOA5	- 1131T > C	rs662799	0.23- 0.30 (C)	C, Ma	2711 (C) 707 (M)	-2.3/- 5.4 mg/dl 1/2 copies; p<0.0001 - 1.2 / - 8.1 mg/dl 1/2 copies; p<0.0001	(Lai et al. 2003)

APOA5	-1131T>C	rs662799	0.34 (C)	A	521 HoCo	-3.3 mg/dl per copy; p<0.001	(Yamada et al. 2007)
APOA5	-3A>G	rs651821	0.07	W	2056 (P)	M; p=0.30; F; p=0.26	(Klos et al. 2006a)
APOA5	-3A>G	rs651821	0.18 (G)	C	2711 (GP)	-2.3/-5.8 mg/dl 1/2 copies; p<0.0001	(Lai et al. 2003)
APOA5	-3A>G	rs651821	0.34 (C)	A	5207 (Ho Co, P)	-2.7 mg/dl per copy; p<0.001	(Yamada et al. 2007)
APOA5	-3A>G	rs651821	0.36 (G)	A	2417 (Ho Co)	-3.9 /- 7.0 mg/dl 1/2 copies; p<0.001	(Yamada et al. 2008)
APOA5	S19W	rs3135506	0.06 (W)	UK	1660 (P)	-1.9 /+1.2 mg/dl (1/2 copies); p=0.02	(Talmud et al. 2002a)
APOA5	56C>G	rs3135506	0.06 (G)	W	2347 (P)	-2.0 mg/dl for carriers; p=0.008	(Lai et al. 2004)
APOA5		rs2072560	0.16 (A)	C	2711 (GP)	-1.9 /-3.9 mg/dl (1/2 copies); p=0.003	(Lai et al. 2003)
APOA5	IVS3+476 G>A	rs2072560		Ma	707 (P)	-0.4 /9.3 mg/dl (1/2 copies); p=0.004	(Qi et al. 2007)
APOA5	V153M	rs3135507		W	2557	F:- 3.5 mg/dl for carriers; p<0.01	(Hubacek 2005)
APOA5	+553	rs2075291	0.07 (T)	A	5206 HoCo	-4.6 mg/dl per copy; p<0.001	(Yamada et al. 2007)
APOA5	Gly185Cys	rs2075291	0.08 (T)	A	2417 HoCo	-5.0 /-11.2 mg/dl (1/2 copies); p<0.001	(Yamada et al. 2008)
APOA5	1259T>C	rs2266788	0.18 (C)	C	2711 (GP)	-2.3 /-3.1 mg/dl 1/2 copies; p<0.0001	(Lai et al. 2003)
APOB		rs11902417	0.78 (G)	E	17723	p= 3.7x10 ⁻⁷	(Waterworth et al. 2010)
APOC3	C455T	rs2854116	0.41 (C)	In	1308 (P)	-3.1/-5.4 mg/dl (1/2 copies); p<0.05	(Lahiry et al. 2007)
APOC3	Pvull	rs618354	0.49	A	F:291 (GP)	F: +0.1/-4.2 mg/dl 1/2 copies;p=0.029	(Kamboh et al. 1999)
APOC3	Sst1 RFLP	rs5128	0.09 (S)	W	M:1219 (P)	M: -1.8 mg/dl for carriers; p=0.04.	(Russo et al. 2001)
APOC3	3'-utr/Sac I	rs5128	0.09 (+)	Hu	713 (P)	-5.0 mg/dl for heteroz.; p=0.0014	(Hegele et al. 1995)

APOC3	3238C > G	rs5128	0.07 (S2)	W	906 (GP)	+1.9 mg/dl for carriers; p=0.079	(Corella et al. 2002)
APOE	Cys112Arg	rs429358	0.16 (A)	N	3575	p=0.001	(Povel et al. 2011)
CETP	G2708A	rs12149545	0.30 (A)	W	2683 GP 556 Cvd	+1.9 mg/dl per copy; p<0.001	(McCaskie et al. 2007)
CETP	G2708A	rs12149545	0.31 (A)	W	709 (CVD)	+1.5 /+3.5 mg/dl (1/2 copies); p=0.0016	(Klerkx et al. 2003)
CETP		rs3764261	0.14 (T)	C	4192	+0.07 mg/dl; p=4.3x10 ⁻¹⁴	(Liu et al. 2011)
CETP	G971A	rs4783961	0.49 (A)	W	709 (CVD)	+1.2/+1.9 mg/dl (1/2 copies); p=0.09	(Klerkx et al. 2003)
CETP	C629A	rs1800775	0.48 (A)	W	7083 (P)	+2.7 /+5.4 mg/dl (1/2 copies); p<0.001	(Borggreve et al. 2005a)
CETP	C629A	rs1800775	0.51 (A)	W	847 M, 873 F (P)	+4.2 mg/dl for homoz.; p<0.002	(Bernstein et al. 2003)
CETP	C629A	rs1800775	0.49 (A)	W	5287 (GP)	+3 /+5 mg/dl (1/2 copies); p=2x10 ⁻²⁹	(Kathiresan et al. 2008)
CETP	C629A	rs1800775	0.42 A	A	4050 (GP)	+2.2/+3.4 mg/dl 1/2 copies; p=3.28x10 ⁻⁹	(Tai et al. 2003b)
CETP	C629A	rs1800775	0.48 (A)	W	2683 GP 556 Cvd	+2.7 mg/dl per copy; p<0.001	(McCaskie et al. 2007)
CETP	C629A	rs1800775	0.40 (A)	W	1214 (CVD) 574 (Co)	CVD: +2.0/3.5mg/dl (1/2 copies); p=0.02 Co: +3.3/6.1 mg/dl (1/2 copies); p=0.05	(Blankenberg et al. 2004)
CETP	C629A	rs1800775	0.44 (A)	W	709 (CVD)	+0.8/3.9 mg/dl (1/2 copies); p<0.0001	(Klerkx et al. 2003)
CETP	C629A	rs1800775	0.50 (A)	W	309 (MI) 757 (Co)	+1.9/6.1 mg/dl (1/2 copies); p<0.0001	(Eiriksdottir et al. 2001)
CETP	C629A	rs1800775	0.48 (A)	W	498 (cvd) 1107(Co)	+2.9/4.4 mg/dl (1/2 copies); p<0.001	(Freeman et al. 2003)
CETP	Taq1B	rs708272	0.40 (B2)		13,677 (Meta)	+1.2 /+3.8 mg/dl 1/2 copies; p<0.0001	(Boekholdt et al. 2005)

CETP	Taq1B	rs708272			>10,000 (Meta)	+4.6 mg/dl for homoz.; p<0.00001	(Boekholdt & Thompson 2003)
CETP	Taq1B	rs708272	0.42 (B2)	W	7083 (P)	+2.7/5.0 mg/dl (1/2 copies); p<0.001	(Borggreve et al. 2005b)
CETP	Taq1B	rs708272	0.44 (B2)	W	2916 (P)	+2.5/4.7 mg/dl (1/2 copies); p<0.001	(Ordovas et al. 2000)
CETP	Taq1B	rs708272	0.43 0.26 (A)	W B	2056 1943 (P)	p<0.01; p<0.02	(Klos et al. 2006b)
CETP	Taq1B	rs708272	0.44 0.27 (A)	W B	8764 (P)	+2.3/5.8 mg/dl (1/2 copies); p<0.001 +3.8/9.8 mg/dl (1/2 copies); p<0.001	(Nettleton et al. 2007)
CETP	Taq1B	rs708272	0.41 (A)	W	1503 (P)	+2 /+5 mg/dl (1/2 copies); p<0.001	(Sandhofer et al. 2008)
CETP	Taq1B	rs708272	0.33 (A)	A	4207 (GP)	+2.5/4.4 mg/dl (1/2 copies); p=1.25x10 ⁻¹⁰	(Tai et al. 2003b)
CETP	Taq1B	rs708272	0.40 (A)	A	1729 (GP)	M: +1.2/3.5 mg/dl (1/2 copies); p=0.096 F: +1.9/6.2 mg/dl (1/2 copies); p<0.001	(Tsujita et al. 2007)
CETP	Taq1B	rs708272	0.42 (A)	W	2683 GP 556 CVD	+2.7 mg/dl per copy; p<0.001	(McCaskie et al. 2007)
CETP	Taq1B	rs708272	0.42 (A)	W	2392 cvd 827 Co	+1.7/3.6 mg/dl (1/2 copies); p<0.001	(Whiting et al. 2005)
CETP	Taq1B	rs708272	0.40 (A)	W	1464 CVD	+2.1/3.0 mg/dl (1/2 copies); p=0.003	(Carlquist & Anderson 2007)
CETP	Taq1B	rs708272	0.41 (A)	W	1200 CV 571 (Co)	+2.6 /+4.3 mg/dl (1/2 copies); p<0.02	(Blankenberg et al. 2004)
CETP	Taq1B	rs708272	0.44 (A)	W	499 CVD 1105 Co	+2.1/3.6 mg/dl (1/2 copies); p<0.001	(Freeman et al. 2003)
CETP	+784CCC	rs34145065	0.39 (A)	W	709 (CVD)	+1.2/3.5 mg/dl (1/2 copies); p=0.0009	(Klerkx et al. 2003)

CETP	A373P	rs5880	0.05 (A)	W	8467 P 1636 CV	5.4 mg/dl for heteroz.; p<0.0001	(Agerholm-Larsen et al. 2000)
CETP	Ile405Val	rs5882			>10,000 (Meta)	+1.9 mg/dl for homoz. ; p<0.00001	(Boekholdt & Thompson 2003)
CETP	A + 16G/Ex.14	rs61212082	0.32 (A)	W	6421 (P)	M: +1.5/2.3 mg/dl (1/2 copies); p=0.002 F: +0.0/+2.3 mg/dl (1/2 copies); p=0.007	(Isaacs et al. 2007)
CETP		rs61212082	0.30 (A)	W	1208 (CVD) 572 (Co)	+1.4 /+3.1 mg/dl (1/2 copies) ; p=0.08 +0.3 /+8.4 mg/dl (1/2 copies); p=0.003	(Blankenberg et al. 2004)
CETP		rs61212082	0.30 (A)	W	498 (CVD) 1108 (Co)	+1.2 /+3.5 mg/dl (1/2 copies); p<0.05 +1.5 /+1.5 mg/dl (1/2 copies); p<0.05	(Freeman et al. 2003)
CETP	D442G	rs2303790b	0.03 (A)	A	3469 (He Ex)	+4.9 mg/dl for heteroz.; p<0.001	(Zhong et al. 1996)
CETP	R451Q	rs1800777	0.04 (A)	W	8467 (P) 1636 (CVD)	5.4 mg/dl for heterozygotes ; p<0.001	(Agerholm-Larsen et al. 2000)
CETP	G + 82A/Ex15	rs1800777	0.03 (A)	W	1071 CV 532 Co	3.6 /5.2 mg/dl for heteroz.; p=0.06/0.07	(Blankenberg et al. 2004)
CETP		rs12596776	0.90 (C)	EA	25,167	p=1.18E-05	(Dumitrescu et al. 2011)
CETP		rs9989419	0.39 (A)	EA	25,167	p=1.71E-53	(Dumitrescu et al. 2011)
LCAT	Gly230Arg			W	156 low 160 high	Variant sig. only in low HDL group	(Miettinen et al. 1998)
LCAT	608C/T	rs5922	.	A	203 (CVD)	Increase in HDL; p=0.015	(Zhang et al. 2003)
LCAT		rs5922		A	150 Str 122 Co	Lower HDL-C in heteroz.; p<0.05	(Zhu et al. 2006)
LCAT	P143L +511C>T			A	190 CVD 209 (Co)	Association with low HDLC; p<0.01	(Zhang et al. 2004)
LCAT		rs2292318	0.12 (A)	W	1442 CVD,Co	Increases HDLC; p=2 x 10 ⁻⁵	(Pare et al. 2007)

LDLR	Exon 2	rs2228671		W	1543 (P)	+3.8 mg/dl for carriers; p=0.0056	(Costanza et al. 2005)
LDLR	1866C > T Asn591Asn	rs688 = rs57911429	0.12 (T)	A	2417 (Ho Co)	+1.5 / +8.5 mg/dl (1/2 copies); p=0.0155	(Yamada et al. 2008)
LDLR	Exon 12/HincII	rs688 = rs57911429	0.39 (+)	Hu	713 (P)	2.3 / 4.3 mg/dl (1/2 copies); p=0.047	(Hegele et al. 1995)
LDLR	2052T > C	rs5925 = rs57369606	0.17 (C)	A	2417 HoCo	+1.2/ +5.4 (1/2 copies); p=0.043	(Yamada et al. 2008)
LIPC	T-710C	rs1077834	0.22 (C)	W	9121 (P)	+3-4% per copy; p<0.001	(Andersen et al. 2003)
LIPC	C-514Ta	rs1800588	0.25 (T)	Va	>24,000 (Meta)	+1.5 / +3.5 mg/dl (1/2 copies); p<0.001	(Isaacs et al. 2004)
LIPC	Pos.-480T	rs1800588	0.21 (T) 0.53 (T)	W B	8897 (P) 2909 (P)	W: +2.2/ +3.8 mg/dl (1/2 copies); p<0.001 B: +1.6/ +4.0 mg/dl (1/2 copies); p<0.001	(Nettleton et al. 2007)
LIPC		rs1800588	0.21 (T)	W	6239 (P)	+1.3/ +4.3 mg/dl (1/2 copies); p<0.001	(Isaacs et al. 2007)
LIPC		rs1800588	0.38 (T)	A	2170 (P)	+2.3 / +2.7 mg/dl (1/2 copies); p=0.001	(Tai et al. 2003a)
LIPC		rs1800588	0.21 (T)	W	5287 (GP)	+1 / +4 mg/dl (1/2 copies); p=4x 10 ⁻¹⁰	(Kathiresan et al. 2008)
LIPC		rs1800588	0.25 (T)	W	2773 (GP)	+1.5 mg/dl per copy; p=0.04	(Talmud et al. 2002b)
LIPC		rs1800588	0.24 (T)	W	3319 CV 1385 Co	+1.0 / +3.8 mg/dl (1/2 copies); p=0.001	(Whiting et al. 2005)
LIPC		rs1800588	0.51 (T)	A	5207 Ho Co	+2.5 mg/dl per copy; p<0.001	(Yamada et al. 2007)
LIPC		rs1800588	0.21 (T)	W	6412 (CVD)	+2.0-2.5 mg/dl per copy; p<0.001	(McCaskie et al. 2006)
LIPC	G -250A	rs2070895	0.22 (A)	W	9121 (P)	+3-4% per copy; p<0.001	(Andersen et al. 2003)
LIPC		rs2070895		W	1543 (P)	+1.5 mg/dl for carriers; p=0.020	(Costanza et al. 2005)
LIPC		rs2070895	0.32 (A)	W	514 (P)	M; p=0.001	(de Andrade et al. 2004)

LIPC		rs2070895	0.23 (A)	W	5585 (P)	+3.9/3.9 mg/dl (1/2 copies); p=8x10 ⁻¹⁰	(Grarup et al. 2008)
LIPC		rs2070895	0.51 (A)	A	5213 HoCo	+2.7 mg/dl per copy; p<0.001	(Yamada et al. 2007)
LIPC		rs2070895	0.39 (A)	A	716 HeEx	+2.1 mg/dl for carriers; p=0.026	(Ko et al. 2004)
LIPC		rs12594375	0.37 (A)	A	2970 (GP)	p=0.00003	(Iijima et al. 2008)
LIPC		rs8023503	0.38 (T)	A	2970 (GP)	p=0.0001	(Iijima et al. 2008)
LIPC	+1075C	rs3829462	0.05 (C)	A	823	+8.0 mg/dl for heterozygotes; p<0.05	(Fang & Liu 2002)
LIPC		rs4775041	0.29C	EA	25,167	p=1.03E-16	(Dumitrescu et al. 2011)
LIPC		rs261332	0.20 (A)	EA	25,167	p=1.99E-13	(Dumitrescu et al. 2011)
LPC		rs261334	0.20 (T)	E	17723	p= 4.9x10 ⁻²²	(Waterworth et al. 2010)
LIPG	-384A > C	rs3813082	0.12 (C)	A	541 (Co)	+1.3/+10.2 mg/dl (1/2 copies); p=0.021	(Hutter et al. 2006)
LIPG		rs3813082	0.12 (C)	A	340 (Kids)	+0.7/+9.8 (1/2 copies); p=0.0086	(Yamakawa-Kobayashi et al. 2003)
LIPG	584 C/T T1111	rs2000813	0.32 (I)	W	495 (GP)	M: 1.2 /+2.7 mg/dl (1/2 copies); p=0.82 F: 0.4 /+1.9 mg/dl (1/2 copies); p=0.09	(Paradis et al. 2003)
LIPG		rs2000813	0.24 (T)	A	541 (Co)	+0.5/+6.1 mg/dl (1/2 copies); p=0.048	(Hutter et al. 2006)
LIPG		rs2000813	0.30 (T)	A	265 CVD 265 Co	+3.7 for carriers; p=<0.02	(Tang et al. 2008)
LIPG		rs2000813	0.29 (T)	W 90%	372 (CVD)	+1.6 /+6.0 mg/dl (1/2 copies); p=0.035	(Ma et al. 2003)
LIPG	C+42T/ln 5	rs2276269	0.44 (T)	W	594 (HDL)	Decreases HDLC; p=0.007	(Mank-Seymour et al. 2004)

LIPG	T+2864C/In8	rs6507931	0.42 (C)	W	594 (HDL)	Decreases HDLC; p=0.004	(Mank-Seymour et al. 2004)
LIPG	2237G > A	rs3744841	0.36 (A)	A	340 (Kids)	4.0 mg/dl /-4.3 mg/dl (1/2 copies); p=0.011	(Yamakawa-Kobayashi et al. 2003)
LPL	D9N; Asp9Asn	rs1801177		-	5067 (Meta)	-3.1 mg/dl for heteroz.; p=0.002	(Wittrup et al. 1999)
LPL	Gly188Glu			-	10,434 (Meta)	- 9.7 mg/dl for heteroz.; p<0.001	(Wittrup et al. 1999)
LPL	N291S	rs268		-	14,912 (Meta)	-4.6 mg/dl for heteroz.; p<0.001	(Wittrup et al. 1999)
LPL	HindIII; Int8	rs320	0.30 (H)	W	520 (P)	+5.5 mg/dl in H - H- vs. H+H+; p=0.025	(Senti et al. 2001)
LPL	HindIII; Int8	rs320	0.26 (H1)	W	1361 (P)	M: +3.5 mg/dl for heteroz.; p=0.0018 F: +4.2 mg/dl for heteroz.; p=0.0212	(Holmer et al. 2000)
LPL	HindIII; Int8	rs320	0.32 (H)	W	906 (GP)	+1.9 mg/dl; p=0.003	(Corella et al. 2002)
LPL	HindIII; Int8	rs320		A	550 (NGT) 465 (DM)	NGT: +3.0 mg/dl for carriers; p<0.05 DM: +1.0 mg/dl for carriers; p<0.05	(Radha et al. 2006)
LPL	HindIII; Int8	rs320	0.27-0.31	NHW, H	615(W); 579(H)	p=0.005	(Ahn et al. 1993)
LPL		rs326	0.44	B	1943 (P)	M; p=0.013; F; p=0.004	(Klos et al. 2006a)
LPL	S447X Ser447Ter	rs328			4388 (Meta)	+1.5 mg/dl for heteroz.; p<0.001	(Wittrup et al. 1999)
LPL	S447X Ser447Ter	rs328	0.10 (G)	W	8968 (P)	+2.8 /+4.0 mg/dl (1/2 copies); p<0.001	(Nettleton et al. 2007)
LPL	S447X Ser447Ter	rs328	0.07 (G)	B	2677 (P)	+3.1 /+12.6 mg/dl (1/2 copies); p<0.001	
LPL	S447X	rs328	0.11 (X)	A	4058 (P)	+3.1 mg/dl; p<0.001	(Lee et al. 2004)
LPL		rs328		W	1543 (P)	+2.7 mg/dl; p=0.0017	(Costanza et al. 2005)
LPL		rs328			25,167	P=5.6E-22	(Dumitrescu et al. 2011)
LPL		rs328	0.09 (G)	W	5287 (GP)	+3 /+5 mg/dl (1/2 copies); p=3 x 10-12	(Kathiresan et al. 2008)

LPL		rs325	0.89 (T)	E	17723	p= 7.8×10-25	(Waterworth et al. 2010)
MLXIP L		rs17145738	0.12 (T)	EA	25,167	p=1.64E-05	(Dumitrescu et al. 2011)
PON1	Q192R	rs662 = rs60480675	0.30 (G)	W	1232 (P)	W: +0.1 / +2.3 mg/dl (1/2 copies) ; p=0.041	(Srinivasan et al. 2004)
PON1	Gln192Arg	rs662 = rs60480675	0.67	B	554	-5.4 / - 6.7 mg/dl (1/2 copies) ; p=0.008	"
PON1		rs662 = rs60480675	0.29 (R)	Hu	738 (P)	-3.1 mg/dl / - 3.1 mg/dl (1/2 copies) ; p=0.001	(Hegele et al. 1995)
PON1		rs662 = rs60480675	0.36 (R)	W-Bra	261 CVD, Co	M: +1.5 / +2.7 mg/dl (1/2 copies) ; p=0.035	(Rios et al. 2007)
PON1	C -107T	rs705379	0.48 (C)	W	710 (CVD)	-3.1/ - 2.3 mg/dl (1/2 copies) ; p=0.006	(Blatter Garin et al. 2006)
PON1	Leu55M	rs85456	0.20 (T)	MA	741	p=0.02	(Chang et al. 2010)
SCARB 1	Exon 8 C>T	rs5888	0.44 (T)	W	865 (P)	+1.9/2.7 mg/dl 1/2 copies;p=0.006	(Morabia et al. 2004)
SCARB 1	C1050T	rs5888	0.49 (T)	W	546 (CVD)	+2.3 / +1.9 mg/dl (1/2 copies); p=0.03	(Boekholdt et al. 2006)

Table 1. Genetic Polymorphisms Associated With HDL-C. MAF=Minor Allele Frequency; Ethn.: A=Asians; AA=African Americans; Am=Amish; A-I=Asian Indian; B=Blacks; C=Chinese; CH=Caribbean Hispanics; In=Inuit; Ma= Malays; N=Netherlands; NHW=Non-Hispanic Whites; H=Hispanics; Hu=Hutteries; Tu=Turks; UK=United Kingdom; W-Bra=Caucasian Brazilians; W= Whites; Va=Various; Non-DM C0=Non diabetic control subjects; MI=Myocardial infarction; NGT=Normal glucose tolerance; DM= Diabetes mellitus; Ho Sta= Hospital staff; HBP= Hypertensive patients; He Ex=Health examination; Cor Ang=coronary angiography; hyperCH=hypercholesterolemia patients; CVD= Cardiovascular Disease; Co=Controls; Ho Co=Hospital based controls; GP=General Population; Meta= Meta Analysis; P=Population based; M= Males; F= females; + =increase; - = decrease; n.s.=not significant; see text for full gene names. Adapted from Boes et al. (2009) with permission from Elsevier.

2.1 Genetic variation in enzymes involved in lipid metabolism and HDL-C levels

Perhaps, the most notable gene in the HDL-C synthesis and metabolism pathways, whose variants have been consistently associated with HDL-C, is the cholesterol ester transfer protein (CETP), which is a key plasma protein that mediates the transfer of esterified cholesterol from HDL to APOB containing particles in exchange for TG. Although complete loss of CETP function is rare and can yield HDL-C levels up to five times higher than normal (Klos and Kullo, 2007), three common polymorphisms (Table 1: TaqIB (rs708272); -

629C>A (rs1800775); Ile405Val (rs5882)) can all modestly inhibit CETP activity and have been consistently associated with higher HDL-C levels (Bernstein et al., 2003; Blankenberg et al., 2004; Boekholdt et al., 2005; Boekholdt and Thompson, 2003; Borggreve et al., 2005; Eiriksdottir et al., 2001; Freeman et al., 2003; Kathiresan et al., 2008a; Klerkx et al., 2003; Tai et al., 2003b; Thompson et al., 2008). The CETP gene is located on chromosome 16 (16q21).

Lipoprotein lipase (LPL) is an enzyme involved in lipolysis of TG-containing lipoproteins such as VLDL and chylomicrons (Miller and Zhan, 2004), which generate free fatty acids (FFA) that can be taken up by the liver, muscle and adipose tissues (Kwan et al., 2007). Thus, LPL affects LDL levels directly (see Section 3.2) may only affect HDL-C levels indirectly (Lewis and Rader, 2005). The human LPL gene is located on chromosome 8 (8p22). Several LPL SNPs have been associated with HDL-C (Table 1) (Ahn et al., 1993; Corella et al., 2002; Holmer et al., 2000; Klos and Kullo, 2007; Klos et al., 2006; Komurcu-Bayrak et al., 2007; Lee et al., 2004; Nettleton et al., 2007; Senti et al., 2001; Wittrup et al., 1999); however, many of them are in strong linkage disequilibrium with each other (e.g., rs320, rs326, rs13702, rs10105606) (Boes et al., 2009; Heid et al., 2008).

Hepatic lipase (HL; LIPC) is a glycoprotein that is synthesized by liver cells (hepatocytes) and catalyzes the hydrolysis of TG and phospholipids (Miller et al., 2003). For example, after hydrolysis of TG by LPL, VLDL particles are reduced to IDL particles and can be further hydrolyzed by HL/LIPC to LDL or taken up by the liver (Kwan et al., 2007). The human HL/LIPC gene is located on chromosome 15 (15q21). Several HL/LIPC SNPs have been associated with HDL-C levels (Table 1) (Andersen et al., 2003; Costanza et al., 2005; de Andrade et al., 2004; Fang and Liu, 2002; Grarup et al., 2008; Iijima et al., 2008; Isaacs et al., 2007; Kathiresan et al., 2008b; Ko et al., 2004; McCaskie et al., 2006; Nettleton et al., 2007; Tai et al., 2003a; Talmud et al., 2002b; Whiting et al., 2005; Yamada et al., 2007). However, the most consistent associations have been observed for rs1800588 and rs2070895 and, several SNPs in the promoter region are in strong LD (Boes et al., 2009).

Endothelial lipase (EL; LIPG) is an enzyme expressed in endothelial cells that, in the presence of HL/LIPC, metabolizes larger (HDL₃) to smaller (HDL₂) HDL-C particles and increases the catabolism of APOA-I (see Section 2.3) (Jaye and Krawiec, 2004). EL/LIPG plays a role in the dyslipidemia component and, possibly, the yet to be established, proinflammatory component of MetSyn (Lamarche and Paradis, 2007) (see Section 5.0). The human EL/LIPG gene is located on chromosome 18 (18q21.1). Several polymorphisms in EL/LIPG have been associated with HDL-C levels (Table 1) (Hutter et al., 2006; Ma et al., 2003; Mank-Seymour et al., 2004; Paradis et al., 2003; Tang et al., 2008; Yamakawa-Kobayashi et al., 2003). However, most of these SNPs have not been as well studied as those in CETP, LPL and EL; and, only the nonsynonymous SNP, rs2000813, has been consistently associated with HDL-C levels in African-American populations (Hutter et al., 2006; Tang et al., 2008; Yamakawa-Kobayashi et al., 2003).

In the presence of cofactor, APOA-I (see Section 2.3), lecithin-cholesterol acyltransferase (LCAT), catalyzes the esterification of free cholesterol and, can metabolize larger HDL-C particles to smaller HDL-C particles (Klos and Kullo, 2007; Miller and Zhan, 2004). The human LCAT is located on chromosome 16 (16q22.1). Although mutations leading to complete loss of LCAT and marked (5-10%) reduction in HDL-C levels are rare and can cause cornea opacifications (fish eye disease) and renal disease (Garg and Simha, 2007), several common polymorphisms in LCAT have been associated, albeit inconsistently, with much more modest changes in HDL-C levels (Table 1) (Boekholdt et al., 2006; Miettinen et al., 1998; Pare et al., 2007; Zhang et al., 2004; Zhu et al., 2006).

Parroxonanase 1 (PON1), inhibits the oxidation of LDL (Mackness et al., 1991) and, therefore, may only indirectly affect antioxidant properties of HDL-C. The human PON1 gene is located on chromosome 7 (7q21.3). Several SNPs in PON1 have been associated with HDL-C levels, most notably, two nonsynonymous SNPs, rs662 and rs3202100, which are in strong LD, but results are inconsistent across studies (Table 1) (Blatter Garin et al., 2006; Hegele et al., 1995; Manresa et al., 2006; Rios et al., 2007; van Aalst-Cohen et al., 2005).

2.2 Genetic variation in receptors and transporters and HDL-C levels

Scavenger receptor class B, type 1 (SCARB1; SR-B1), which is highly expressed in liver and steroidogenic tissues (testes, ovaries, adrenal) (Cao et al., 1997), has been shown to participate in the uptake of HDL in animals by transferring cholesterol from the HDL-C particle and releasing the lipid-depleted HDL particle into the circulation (Acton et al., 1996; Miller et al., 2003). The human SCARB1 gene is located on chromosome 12 (12q24.31). Only a few studies have examined potential associations between SCARB1 polymorphisms and HDL-C levels (Table 1) (Boekholdt et al., 2006; Costanza et al., 2005; Hsu et al., 2003; Morabia et al., 2004; Osgood et al., 2003; Roberts et al., 2007). The most well studied polymorphism has been rs5888; however, the association with rs5888 and HDL-C levels was only significant among Caucasian (White, W) males in one study (Morabia et al., 2004), Amish females (Roberts et al., 2007) and Caucasian CVD patients (Boekholdt et al., 2006).

The LDL receptor (LDLR) and LDLR-related protein participate in the uptake of LDL and chylomicron remnants by hepatocytes (Kwan et al., 2007) and, therefore, may only indirectly affect HDL-C levels. The human LDLR is located on chromosome 19 (19p13.2). Although some common polymorphisms in LDLR have been associated with HDL-C levels (Table 1: (Costanza et al., 2005; Hegele et al., 1995; Yamada et al., 2008), their impact is likely greater on LDL-C levels (see Section 3.1).

The ATP-binding cassette transporter A1 (ABCA1), which is highly expressed in the liver, steroidogenic tissues and macrophages, plays a key role in 'reverse cholesterol transport' by mediating the efflux of cholesterol and phospholipids from macrophages to the nascent lipid-free, APOA-1 HDL particle (Cavelier et al., 2006; Miller et al., 2003). The human ABCA1 gene is located on chromosome 9 (9q31.1). Due to its functional importance, genetic variants in this gene have been well investigated but many of them are quite rare including the homozygous deletion that leads to Tangier's disease that is characterized by very low HDL-C levels (~5 mg/dl), orange colored tonsils, peripheral neuropathy and, sometimes, premature CHD (Garg and Simha, 2007). Several common polymorphisms have been fairly consistently associated with more modest changes in HDL-C levels but different variants appear to drive this association in different ethnic groups (Table 1) (Clee et al., 2001; Costanza et al., 2005; Frikke-Schmidt et al., 2004; Hodoglugil et al., 2005; Kathiresan et al., 2008b; Klos et al., 2006; Porchay et al., 2006; Shioji et al., 2004b; Whiting et al., 2005).

2.3 Genetic variation in apolipoproteins and HDL-C levels

Apolipoprotein A-1 (APOA1; APOA-I) is a ligand required for HDL-C binding to its receptors including SCARB1 and ABCA1 and, is an important cofactor in 'reverse cholesterol transport' (Miller et al., 2003; Remaley et al., 2001; Rigotti et al., 1997). The

human APOA1 gene is located on chromosome 11 (11q23-24). APOA-I is a major constituent of HDL particles and deletions leading to complete APOA-I deficiency are rare but lead to HDL deficiency (HDL-C <10 mg/dl) and sometimes CHD (Garg and Simha, 2007). Several common polymorphisms in APOA-I have been associated with more modest reductions in HDL-C but results across studies are inconsistent (Table 1) (Brown et al., 2006; Kamboh et al., 1999b; Larson et al., 2002; Shioji et al., 2004a).

Apolipoprotein A-4 (APOA4; APOA-IV) is a potent activator of LCAT and modulates the activation of LPL and transfer of cholesteryl esters from HDL to LDL (Kwan et al., 2007). The human APOA4 gene is located on chromosome 11 near APOA1 (11q23) and is part of what is known as the APOA1/C3/A4/A5 gene cluster. Polymorphisms in APOA4 have not been as well studied; however, the nonsynonymous SNP, rs5110 (Gln360His), has recently been associated with reduced HDL-C levels in Brazilian elderly (Ota et al., 2011) and coronary artery calcification (CAC) progression, a marker of subclinical atherosclerosis, in patients with Type I Diabetes Mellitus (T1DM) (Kretowski et al., 2006). The rs675 polymorphism has been associated with reduced HDL-C levels in females with T2DM (Qi et al., 2007).

Apolipoprotein A-5 (APOA5; APOA-V) is located predominantly on TG-rich chylomicrons and VLDL and activates LPL (Hubacek, 2005). The human APOA5 gene is located on chromosome 11 (11q23) in the APOA1/C3/A4/A5 gene cluster. Several APOA5 SNPs have been associated with reduced HDL-C levels; and, perhaps, the most well studied and consistent associations have been observed for rs651821 and rs662799 (Table 1) (Grallert et al., 2007; Hubacek, 2005; Klos et al., 2006; Lai et al., 2003; Qi et al., 2007; Talmud et al., 2002a; Yamada et al., 2008; Yamada et al., 2007).

Apolipoprotein C-3 (APOC3; APOC-III) is an inhibitor of LPL and is transferred to HDL during the hydrolysis of TG-rich lipoproteins (Kwan et al., 2007; Miller and Zhan, 2004). The human APOC3 gene is located on chromosome 11 (11q23) in the APOA1/C3/A4/A5 gene cluster. Although several APOC3 SNPs have been identified and investigated, associations between these SNPs and HDL-C levels have been quite inconsistent (Table 1) (Arai and Hirose, 2004; Brown et al., 2006; Corella et al., 2002; Hegele et al., 1995; Kamboh et al., 1999a; Lahiry et al., 2007; Pallaud et al., 2001; Qi et al., 2007; Russo et al., 2001).

Chylomicron remnants, VLDL and IDL particles are rich in apolipoprotein E (APOE) and APOE is a critical ligand for binding to hepatic receptors that remove these particles from the circulation (Kwan et al., 2007). Mutations in APOE are well known to modify LDL-C levels; however, their independent influence on HDL-C levels remains controversial (Sviridov and Nestel, 2007). Nevertheless, associations between APOE SNPs and HDL-C levels in large scale studies have been fairly consistent (Costanza et al., 2005; Frikke-Schmidt et al., 2000; Gronroos et al., 2008; Kataoka et al., 1996; Srinivasan et al., 1999; Volcik et al., 2006; Wilson et al., 1994; Wu et al., 2007).

2.4 GWAS and HDL-C Levels

Results from genomewide association studies (GWAS) have confirmed associations between polymorphisms in viable candidate genes including CETP, LPL, HL/LIPIC, EL/LIPG, ABCA1, LCAT and the APOA1/C3/A4/A5 gene cluster and HDL-C levels (Boes et al., 2009). GWAS have also identified several novel putative loci, which are discussed in detail in a recent review (Teslovich et al., 2010).

3. Genetic variants in lipid metabolism and LDL-C levels

3.1 Genetic variation in enzymes, receptors and transporters and LDL-C levels

LDL-C is a widely accepted risk factor for atherosclerotic cardiovascular diseases. The most marketed drugs for lowering LDL-C are statins, which inhibit hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR), the rate limiting enzyme in cholesterol synthesis that is normally suppressed (Endo, 1992). The human HMGCR gene is located on chromosome 5 (5q13.3-14). Only a few common HMGCR polymorphisms have been associated with LDL-C levels including rs3846662, which was identified through GWAS (Table 2) (Burkhardt et al., 2008; Hiura et al., 2010; Polisecki et al., 2008; Teslovich et al., 2010).

As mentioned above, the LDL receptor (LDLR) regulates the uptake of LDL and chylomicron remnants by hepatocytes (Kwan et al., 2007) and, the human LDLR gene is located on chromosome 19 (19p13.2). Familial (or monogenic) hypercholesterolemia (FH: OMIM No. 143890), which is due to mutations in LDLR occurring at a frequency of approximately 1 in 500 (heterozygotes) to 1 in 1,000,000 (homozygotes), is one of the most common inherited metabolic diseases and results in a reduced number of LDL receptors and, in heterozygotes, a 2- to 3-fold increase in LDL-C levels and, in homozygotes, complete loss of LDLR function and a greater than 5-fold increase in LDL-C (Garg and Simha, 2007). A few common polymorphisms in LDLR have been identified and associated with more modest changes in LDL-C levels, most notably, rs6511720, which was highly significantly associated with LDL-C in a recent meta analysis (Table 2) (Teslovich et al., 2010; Willer et al., 2008).

ATP-binding cassette transporters G5 and G8 (ABCG5/8) regulate the efflux of cholesterol back into the intestinal lumen and, in hepatocytes, the efflux of cholesterol into bile (Graf et al., 2003). The human ABCG5/8 gene cluster is located on chromosome 2 (2p21). A rare autosomal recessive mutation in ABCG5/8 leads to sitosterolemia characterized by xanthomas, premature atherosclerosis and other features (Berge et al., 2000). Only a couple of common variants in ABCG5/8 have been associated with LDL-C levels and a recent meta-analysis failed to find associations between ABCG5/G8 polymorphisms including, ABCG8 rs6544718, and plasma lipid levels (Table 2) (Jakulj et al., 2010; Teslovich et al., 2010)

3.2 Genetic variation in lipoproteins and LDL-C levels

Apolipoprotein B (APOB; main isoform: ApoB-100) is responsible for the recognition and uptake of LDL by LDLR, which clears approximately 60-80% of the LDL in 'normal' individuals with the remaining taken up by LRP or SCARB1 (Kwan et al., 2007). The human APOB gene is located on chromosome 2 (2p23-24). Familial defective APOB (FDB: OMIM No. 144010) is an autosomal codominant disorder due to mutations in APOB that are a bit more rare than FH mutations at approximately 1 in 500 to 1 in 700 resulting in lower LDL-C levels than in FH patients (Garg and Simha, 2007). Common polymorphisms have also been identified and associated with more modest changes in LDL-C (Table 2) (Haas et al., 2011; Teslovich et al., 2010; Waterworth et al., 2010; Willer et al., 2008).

As mentioned above, APOE is a critical ligand for binding chylomicron remnants, VLDL and IDL particles to hepatic receptors to remove these particles from the circulation (Kwan et al., 2007). The human APOE gene is located on chromosome 19 (19q13.2). The structural APOE gene is polymorphic with three common alleles, designated as $\epsilon 2$, $\epsilon 3$ and $\epsilon 4$ which encode for E2, E3 and E4 proteins, respectively. Although several APOE polymorphisms have been identified, the APOE $\epsilon 4$ allele has been the most consistently associated with CHD and LDL-C levels (Table 2) (Anoop et al., 2010; Chang et al., 2010; Eichner et al., 2002; Teslovich et al., 2010; Willer et al., 2008).

Gene	Polym.	rs Number	MAF	Ethn.	Sample Size	Results (Effect Size, p-value)	Reference
ABCG8		rs4299376	0.30 (G)	E	95,454 (Meta)	+2.75 mg/dl; p=2x10 ⁻⁸	(Teslovich et al. 2010)
ABCG8	A632V	rs6544718		Va	982	p=0.02	(Jakulj et al. 2010)
APOB		rs562338	0.18 (A)	Va	10,849	+4.89 mg/dl; p=3.6 X 10 ⁻¹²	(Willer et al. 2008)
APOB		rs754523	0.28 (A)	Va	6,542	+2.78 mg/dl; p=1.3 X10 ⁻⁶	(Willer et al. 2008)
APOB		rs693	0.42 (G)	Va	3,222	+2.44 mg/dl; p=0.0034	(Willer et al. 2008)
APOB	Thr98Ile	rs1367117	0.30 (A)	E	95,454 (Meta)	+4.05 mg/dl; p=4x10 ⁻¹¹⁴	(Teslovich et al. 2010)
APOB		rs7575840	0.28 (T)	F	5054	0.131 p= 3.88x10 ⁻⁹	(Haas et al. 2011)
APOB		rs515135	0.19 (A)	Va	982	p=2.4X10 ⁻²⁰	Waterworth et al. (2010)
APOE		rs4420638	0.17 (G)	E	95,454 (Meta)	+7.14 mg/dl; p=9x10 ⁻¹⁴⁷	(Teslovich et al. 2010)
APOE	Arg176 Cys	rs7412	0.06 (T)	N-HB	683	-22.52mg/dl; p< 0.0001	(Chang et al. 2010)
APOE	Cys130 Arg	rs429358	0.076 (T)	M-A	739	10.54mg/dl; p< 0.0001	(Chang et al. 2010)
APOC1		rs4420638	0.82 (A)	Va	10,806	+6.61 mg/dl; p = 4.9 X10 ⁻²⁴	(Willer et al. 2008)
APOE/C1/C4		rs10402271	0.67 (T)	Va	6,519	+2.62 mg/dl; p =1.5 X 10 ⁻⁵	(Willer et al. 2008)
LDLR		rs6511720	0.11 (T)	E	95,454 (Meta)	-6.99 mg/dl; p=4x10 ⁻¹¹⁷	(Teslovich et al. 2010)
LDLR		rs6511720	0.90 (T)	Va	7,442	+9.17 mg/dl; p =3.3 X 10 ⁻¹⁹	(Willer et al. 2008)
PCSK9		rs11206510	0.81 (C)	Va	10,805	+3.04 mg/dl; p=5.4 X 10 ⁻⁷	(Willer et al. 2008)
PCSK9		rs2479409	0.30 (G)	E	95,454 (Meta)	+2.01mg/dl; p= 2x10 ⁻²⁸	(Teslovich et al. 2010)
PCSK9	A443T Ala443Thr	rs28362263	0.06 (A)	B	1750	95.5 vs. 106.9 mg/dl;p<0.001	(Huang et al. 2009)
PCSK9	C679X	rs28362286		B	1750	81.5 vs. 106.9 mg/dl;p<0.001	(Huang et al. 2009)
PCSK9	E670G	rs505151	0.11 (G)	W	691	P=0.001	(Chen et al. 2005)
PCSK9		rs11206510	0.81 (T)	EA	21,986 (Meta)	p=1.44E-05	(Dumitrescu et al. 2011)
SORT1		rs629301	0.22 (G)	E	95,454 (Meta)	-5.65 mg/dl; p=1 x 10 ⁻¹⁷⁰	(Teslovich et al. 2010)

Table 2. Genetic Polymorphisms Associated with LDL-C. See Table 1 legend.

3.3 Genetic variation in proteases and LDL-C levels

Proprotein convertase subtilisin-like kexin type 9 (PCSK9) is a serine protease that degrades hepatic LDLR in endosomes (Maxwell et al., 2005). The human PCSK9 gene is located on chromosome 1 (1p32.3). A mutation in PCSK9 results in an autosomal dominant form of hypercholesterolemia (OMIM No. 607786) with clinical features similar to FH patients (Garg and Simha, 2007). Over 50 variants in PCSK9 have been shown to affect circulating levels of cholesterol; however, most of these are relatively rare (see Davignon et al., 2010) for a complete list). The number of common polymorphisms in PCSK9 is substantially less with only a few SNPs having been associated with changes in LDL-C levels (Table 2) (Chen et al., 2005; Evans and Beil, 2006; Huang et al., 2009; Teslovich et al., 2010; Willer et al., 2008).

3.4 GWAS and LDL-C Levels

GWAS have confirmed associations between polymorphisms in viable candidate genes including APOB, APOE, LDLR and PCSK9, and have identified novel SNPs associated with LDL-C levels with strong biological plausibility including an inhibitor of lipase (ANGPTL3), see Section 4.1 and a transcription factor activating triglyceride synthesis (MLXIPL) see Section 4.2 (Teslovich et al., 2010).

4. Genetic variants in lipid metabolism and TG levels

Plasma triglycerides (TG) integrate multiple TG-rich lipoprotein particles, predominantly, intestinally synthesized chylomicrons in the postprandial state and hepatically synthesized VLDL in the fasted state. Therefore, not surprisingly, there is considerable overlap between genetic variants associated with HDL-C and LDL-C levels as well as TG levels. For example, the Global Lipids Genetics Consortium (GLGC) found that 15 of the 32 loci associated with TG levels were also jointly associated with HDL-C levels, explaining 9.6% of the total variation in plasma TG, which corresponded to 25–30% of the total genetic contribution to TG variability (Teslovich et al., 2010). However, the joint associations reported do not appear additionally adjusted for the other lipid phenotype. Furthermore, certain loci appear to be more strongly associated with one lipid phenotype over the other while others have similar effect sizes; and, genetic heterogeneity between loci clearly exists between major ethnic groups.

4.1 Genetic variation in aolipoproteins and TG levels

As mentioned above (see Section 3.2), APOB is the backbone of atherogenic lipoproteins and is located on chromosome 2 (2p23-24). A rare monogenic autosomal recessive disorder called homozygous hypobetalipoproteinemia and rare autosomal codominant disorder called familial hypobetalipoproteinaemia (HHBL and FHBL, respectively: OMIM No. 107730), characterized by very low (<5th percentile of age- and sex-specific values) of plasma TG (and LDL-C) levels, which are caused by rare mutations in APOB (Burnett and Hooper, 2008; Di et al., 2009). Although common APOB polymorphisms have primarily been associated with LDL-C levels (Benn, 2009), GWAS has revealed that a common SNP in APOB, rs1042034, is associated with TG (Johansen and Hegele, 2011; Teslovich et al., 2010).

Common polymorphisms in the APOA1/C3/A4/A5 gene cluster, located on chromosome 11 (11q23), have been associated with HDL-C levels (see Section 2.3) as well as TG levels (Teslovich et al., 2010; Willer et al., 2008). A SNP in the APOE gene, rs439401, has also been shown to be strongly associated with TG levels in a recent GWAS meta analyses (Johansen and Hegele, 2011; Teslovich et al., 2010).

z	Polym.	rs Number	MAF	Ethn.	Sample Size	Results (Effect Size, p-value)	Reference
ANGPTL3		rs2131925	0.32 (G)	E	96,598 (Meta)	-4.94mg/dl; p=9x10 ⁻⁴³	(Teslovich et al. 2010)
ANGPTL3		rs1748195	0.70 (G)	Va	9,559	7.12 mg/dl; p=5.4x10 ⁻⁸	(Willer et al. 2008)
APOA5		rs964184	0.13 (G)	E	96,598 (Meta)	+16.95mg/dl; p=7x10 ⁻²⁴⁰	(Teslovich et al. 2010)
APOA5/A4/C3/A1		rs12286037	0.94 (C)	Va	9,738	25.82 mg/dl; p=1.6x10 ⁻²²	(Willer et al. 2008)
APOA5		rs662799	0.05 (A)	Va	3,248	16.88 mg/dl p=2.7x10 ⁻¹⁰	(Willer et al. 2008)
APOA5/A4/C3/A1		rs2000571	0.17 (G)	Va	3,209	6.93 mg/dl; p=8.7x10 ⁻⁵	(Willer et al. 2008)
APOA5/A4/C3/A1		rs486394	0.28 (A)	Va	3,597	1.50 mg/dl; p=0.0073	(Willer et al. 2008)
APOE		rs439401	0.40 (C)	C	4,192	p=2.2x10 ⁻⁵	(Liu et al. 2011)
APOE		rs439401	0.64 (C)	Va	Meta	p=5.5x10 ⁻³⁰	Johansen et al. (2010)
LIPC/HL		rs4775041	0.67 (G)	Va	8,462	3.62 mg/dl; p=2.9x10 ⁻⁵	(Willer et al. 2008)
LIPC/HL		rs261342	0.22 (G)	Va	Meta	p=2.0x10 ⁻¹³	Johansen et al. (2010)
LPL		rs12678919	0.12 (G)	E	96,598 (Meta)	-13.64 mg/dl p=2x10 ⁻¹¹⁵	(Teslovich et al. 2010)
LPL		rs10503669	0.90 (A)	Va	9,711	11.57 mg/dl; p=1.6x10 ⁻¹⁴	(Willer et al. 2008)
LPL		rs2197089	0.58 (A)	Va	3,202	3.38 mg/dl; p=0.0029	(Willer et al. 2008)
LPL		rs6586891	0.66 (A)	Va	3,622	4.60 mg/dl; p=5x10 ⁻⁴	(Willer et al. 2008)
LPL	S447X	rs328	0.90 (C)	EA	24,258	p=4.16E-30	(Dumitrescu et al. 2011)
LPL	S447X	rs328	0.10 (X)	Va	43,242	-0.15 (-0.12- -0.19) mmol/l	(Sagoo et al. 2008)
LPL	D9N	rs1801177	0.03 (N)	Va	21,040	0.14 (0.08-0.20) mmol/l	(Sagoo et al. 2008)
LPL	N291S	rs368	0.03 (S)	Va	27,204	0.19 (0.12-0.26) mmol/l	(Sagoo et al. 2008)
LPL		rs326	0.18 (G)	C	4,192	p=2.3x10 ⁻⁶	(Liu et al. 2011)
LRP1		rs11613352	0.23 (T)	E	96,598 (Meta)	-2.70 mg/dl p=4x10 ⁻¹⁰	(Teslovich et al. 2010)
MLXIPL		rs17145738	0.12 (T)	E	96,598 (Meta)	-9.32 mg/dl p=6x10 ⁻⁵⁸	(Teslovich et al. 2010)
MLXIPL		rs17145738	0.84 (T)	Va	9,741	8.21 mg/dl; p=5x10 ⁻⁸	(Willer et al. 2008)
MLXIPL		rs7811265	0.81 (A)	Va	Meta	7.91 mg/dl p=9.0x10 ⁻⁵⁹	(Johansen et al. 2011)

Table 3. Genetic Polymorphisms Associated With TG Levels. See Table 1 legend.

Angiopoietin-like 3 protein (ANGPTL3) inhibits LPL catalytic activity but this process is reversible (Shan et al., 2009; Shimizugawa et al., 2002). A monogenic autosomal recessive disorder called familial combined hypolipidemia (FCH: OMIM No. 605019), characterized by very low TG levels, is genetically complex and poorly understood; however, mutations in ANGPTL3 are believed to play a role. Common polymorphisms in ANGPTL3, most notably, rs2131925, have been associated with more modest changes in TG levels (Johansen and Hegele, 2011; Keebler et al., 2009; Lanktree et al., 2009; Teslovich et al., 2010; Willer et al., 2008). Sequencing individuals in the Dallas Heart Study has identified several additional nonsynonymous ANGPTL3 variants affecting TG levels (Musunuru et al., 2010); however, these SNPs require further investigation in other populations.

4.2 Genetic variation in enzymes and transcription factors and TG levels

As mentioned above (see Section 2.1), LPL is an enzyme that hydrolyzes TG-rich particles in peripheral tissues (muscle, macrophages, adipose) generating FFA and glycerol for energy metabolism and storage (Goldberg, 1996). More than 100 mutations in LPL have been identified (Murthy et al., 1996); however, only a few common nonsynonymous SNPs have been consistently associated with TG levels including rs1801177, rs328 and rs268 (Mailly et al., 1995; Rip et al., 2006; Sagoo et al., 2008; Teslovich et al., 2010; Willer et al., 2008). Two SNPs, rs1801177 and rs328, have also been consistently associated with CHD; however, there is fairly strong LD between these SNPs, at least in Caucasians (Sagoo et al., 2008).

MLX interacting protein like (MLXIPL) locus encodes a transcription factor of the Myc/Max/Mad superfamily which activates, in a glucose-dependent manner, carbohydrate response element binding protein (CREBP) that is expressed in lipogenic tissues coordinating the subsequent activation of lipogenic enzymes such as fatty acid synthase (FAS) to convert dietary carbohydrate to TG (Iizuka and Horikawa, 2008). The human MLXIPL gene is located on chromosome 7 (7q11.23). Although initially identified through GWAS, the rs1745738 polymorphism has been replicated in other studies (Johansen and Hegele, 2011; Teslovich et al., 2010; Wang et al., 2008; Willer et al., 2008).

5. Genetic variants in dyslipidemia and the Metabolic Syndrome (MetSyn)

As mentioned in the Introduction (see Section 1.0), MetSyn is a clustering of traits including dyslipidemia as well as obesity, hypertension and insulin resistance/dysglycemia. Undoubtedly, there is complex interplay between genetic determinants of each of these traits and 'environmental' factors including those related to lifestyle (diet, exercise, sleep) and those related to toxin exposure. Due to space limitations, we focus only on the genetic determinants of dyslipidemia that overlap with MetSyn defined as a single, unifying trait and refer the reader to other reviews for genetic determinants of the other traits involved in MetSyn (Joy et al., 2008; Monda et al., 2010; Pollex and Hegele, 2006; Sharma and McNeill, 2006) and their interactions with lifestyle factors (Adamo and Tesson, 2008; Garaulet et al., 2009; Ordovas and Shen, 2008; Phillips et al., 2008) and toxins (Andreassi, 2009).

Lipoprotein related genes with common SNPs associated with MetSyn (as defined by NCEP ATP III and AHA/NHLBI criteria) and HDL-C, LDL-C or TG levels include APOA5 and APOC3 (Table 4) (Grallert et al., 2007; Joy et al., 2008; Miller et al., 2007; Pollex et al., 2006; Pollex and Hegele, 2006; Yamada et al., 2008). Enzymes involved in lipid metabolism with genetic polymorphisms that have also been associated with MetSyn (using the NCEP ATP III criteria) appear limited to the nonsynonymous SNP in LPL, rs328 (Table 4) (Joy et al., 2008;

Komurcu-Bayrak et al., 2007). Several SNPs in the LDLR have been associated with MetSyn (using AHA/NHLBI criteria) and LDL-C or HDL-C (Joy et al., 2008; Yamada et al., 2008).

Gene	Polymorphism	rs Number	Ethn.	Sample Size	Results (p-value)	Reference	Comments (definition)
APOA5	-1131T→C		J	1788	p< 0.0009	(Yamada et al. 2007)	NCEP ATP III
APOA5	c.56C→G		C	3124	p=0.026	(Grallert et al. 2007)	NCEP ATP III
APOA5	-3A→G		J	2417	p< 0.0001	(Yamada et al. 2008)	AHA/NHLBI
APOC3	-455T→C		O-C	515	p=0.029*	(Miller et al. 2007) (Pollex et al. 2006)	*Women only NCEP ATP III
LDLR	2052TmC		J	2417	p=0.0005	(Yamada et al. 2008)	AHA/NHLBI
LPL	S447X		Tu	1586	p=0.04	(Komurcu-Bayrak et al. 2007)	NCEP ATP III
LPL		rs295	Va	1407	OR= 0.7; p=2.1 x 10 ⁻³	(Grassi et al. 2011)	NCEP ATP III

Table 4. Genetic Polymorphisms in Lipid Metabolism Associated with MetSyn. See Table 1 legend. WHO= World Health Organization; NCEP ATP III=National Cholesterol Education Program Adult Treatment Panel III, IDF=International Diabetes Federation; AHA=American Heart Association; NHLBI=National Heart, Lung, and Blood institute.

6. Genetic variants in dyslipidemia and MetSyn: Future directions

Given the polygenic nature and multi-level complexity of Dyslipidemia and MetSyn, a better understanding of the genetic determinants of each intermediate (lower level) phenotype as well as the collective integration of these traits as unifying syndromes (higher/hierarchical level) is needed, which will require more elegant statistical modeling methods and, perhaps, a paradigm shift in the way in which we think about dissecting genetic and environmental factors in complex traits. As stated throughout this chapter, there is considerable overlap between genetic variants associated with HDL-C, LDL-C and TG levels as well MetSyn as a unifying trait. As a result, there is great need to understand not only the aggregate effects of multiple variants in each of these genes but to also understand how the effects of variation in one gene are modified in the presence of other genes.

Aggregate effects of multiple variants in genes affecting dyslipidemia and MetSyn related traits have included calculation of 'risk scores', which simply add the number of 'risk alleles' in a weighted or unweighted manner. For example, unweighted risk scores were constructed by summing the number of 'TG-raising' alleles at 32 loci and placed in 'risk bins' (categories) to show that higher risk scores were significantly associated with patients with hypertriglyceridemia (HTG) compared to controls (Johansen and Hegele, 2011; Teslovich et al., 2010). Increasing genotype risk scores comprised by summing risk alleles in 9 common SNPs were associated with decreasing HDL-C levels (Kathiresan et al., 2008a).

We have used the multivariate statistical framework of structural equation modeling (SEM) to evaluate multiple genetic determinants of MetSyn and aggregate effects of individual genes by modeling MetSyn as a second-order factor together with multiple putative candidate genes represented by latent constructs, which we mathematically defined by multiple SNPs in each gene (Nock et al., 2009b). Using this approach with the Framingham Heart Study (Offspring Cohort, Exam 7; Affymetrix 50k Human Gene Panel) data, we found that the CETP gene had a very strong association with the Dyslipidemia factor but little effect on MetSyn directly. Furthermore, we found that the effects of the CSMD1 gene diminished when modeled simultaneously with six other candidate genes, most notably CETP and STARD13. Work to identify the genetic determinants of 'Syndrome Z', modeled as a higher-order, unifying syndrome defined by 5 first-order factors (dyslipidemia, insulin resistance, obesity, hypertension, sleep disturbance) (Nock et al., 2009a) using the latent gene construct SEM approach is underway.

The use of other forms of 'causal modeling' (edge/node; integrative genetics) has been proposed (Lusis et al., 2008), particularly, to improve our understanding of differential effects by gender as well as to better understand how maternal nutrition and epigenetics affect MetSyn. Furthermore, a complex model for the genetic determinants of MetSyn associated phenotypes was recently proposed and, using gene enrichment analysis and protein-protein interaction network approaches, the retinoid X receptor and farnesoid X receptor (FXR) were identified as key players in MetSyn given their multiple interactions with metabolism, cell proliferation and oxidative stress (Sookoian and Pirola, 2011). However, more elegant kinetic models may be required to understand the true influence of genetic variants on Dyslipidemia and MetSyn given the presence of multiple feedback loops and reversible reactions (Bakker et al., 2010; Gutierrez-Cirlos et al., 2011).

7. Acknowledgement

This work was supported, in part, by the National Institutes of Health/National Cancer Institute Grant [K07CA129162] awarded to NLN.

8. References

2001. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). *JAMA* 285: 2486-2497.
- Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. 1996. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. *Science* 271: 518-520.
- Adamo KB, Tesson F. 2008. Gene-environment interaction and the metabolic syndrome. *Novartis. Found. Symp.* 293: 103-119.
- Adiels M, Olofsson SO, Taskinen MR, Boren J. 2006. Diabetic dyslipidaemia. *Curr. Opin. Lipidol.* 17: 238-246.
- Ahn YI, Kamboh MI, Hamman RF, Cole SA, Ferrell RE. 1993. Two DNA polymorphisms in the lipoprotein lipase gene and their associations with factors related to cardiovascular disease. *J. Lipid Res.* 34: 421-428.

- Alberti KG, Eckel RH, Grundy SM, et al. 2009. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation* 120: 1640-1645.
- Alberti KG, Zimmet P, Shaw J. 2005. The metabolic syndrome--a new worldwide definition. *Lancet* 366: 1059-1062.
- Alberti KG, Zimmet PZ. 1998. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet. Med.* 15: 539-553.
- Andersen RV, Wittrup HH, Tybjaerg-Hansen A, Steffensen R, Schnohr P, Nordestgaard BG. 2003. Hepatic lipase mutations, elevated high-density lipoprotein cholesterol, and increased risk of ischemic heart disease: the Copenhagen City Heart Study. *J. Am. Coll. Cardiol.* 41: 1972-1982.
- Andreassi MG. 2009. Metabolic syndrome, diabetes and atherosclerosis: influence of gene-environment interaction. *Mutat. Res.* 667: 35-43.
- Anoop S, Misra A, Meena K, Luthra K. 2010. Apolipoprotein E polymorphism in cerebrovascular & coronary heart diseases. *Indian J. Med. Res.* 132: 363-378.
- Arai Y, Hirose N. 2004. Aging and HDL metabolism in elderly people more than 100 years old. *J. Atheroscler. Thromb.* 11: 246-252.
- Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. 2004. Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. *Curr. Med. Res. Opin.* 20: 1691-1701.
- Austin MA, King MC, Vranizan KM, Krauss RM. 1990. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. *Circulation* 82: 495-506.
- Bakker BM, van EK, Jeneson JA, van Riel NA, Bruggeman FJ, Teusink B. 2010. Systems biology from micro-organisms to human metabolic diseases: the role of detailed kinetic models. *Biochem. Soc. Trans.* 38: 1294-1301.
- Balkau B, Charles MA. 1999. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). *Diabet. Med.* 16: 442-443.
- Benn M. 2009. Apolipoprotein B levels, APOB alleles, and risk of ischemic cardiovascular disease in the general population, a review. *Atherosclerosis* 206: 17-30.
- Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J, Kwiterovich P, Shan B, Barnes R, Hobbs HH. 2000. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. *Science* 290: 1771-1775.
- Bernstein MS, Costanza MC, James RW, Morris MA, Cambien F, Raoux S, Morabia A. 2003. No physical activity x CETP 1b.-629 interaction effects on lipid profile. *Med. Sci. Sports Exerc.* 35: 1124-1129.
- Blankenberg S, Tiret L, Bickel C, et al. 2004. [Genetic variation of the cholesterol ester transfer protein gene and the prevalence of coronary artery disease. The AtheroGene case control study]. *Z. Kardiol.* 93 Suppl 4: IV16-IV23.
- Blatter Garin MC, Moren X, James RW. 2006. Paraoxonase-1 and serum concentrations of HDL-cholesterol and apoA-I. *J. Lipid Res.* 47: 515-520.

- Boekholdt SM, Sacks FM, Jukema JW, et al. 2005. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. *Circulation* 111: 278-287.
- Boekholdt SM, Souverein OW, Tanck MW, et al. 2006. Common variants of multiple genes that control reverse cholesterol transport together explain only a minor part of the variation of HDL cholesterol levels. *Clin. Genet.* 69: 263-270.
- Boekholdt SM, Thompson JF. 2003. Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. *J. Lipid Res.* 44: 1080-1093.
- Boes E, Coassin S, Kollerits B, Heid IM, Kronenberg F. 2009. Genetic-epidemiological evidence on genes associated with HDL cholesterol levels: a systematic in-depth review. *Exp Gerontol.* 44: 136-160.
- Borggreve SE, Hillege HL, Wolffenbittel BH, de Jong PE, Bakker SJ, van der Steege G, van TA, Dullaart RP. 2005. The effect of cholesteryl ester transfer protein -629C->A promoter polymorphism on high-density lipoprotein cholesterol is dependent on serum triglycerides. *J. Clin. Endocrinol. Metab* 90: 4198-4204.
- Brown CM, Rea TJ, Hamon SC, Hixson JE, Boerwinkle E, Clark AG, Sing CF. 2006. The contribution of individual and pairwise combinations of SNPs in the APOA1 and APOC3 genes to interindividual HDL-C variability. *J. Mol. Med. (Berl)* 84: 561-572.
- Burkhardt R, Kenny EE, Lowe JK, et al.. 2008. Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13. *Arterioscler. Thromb. Vasc. Biol.* 28: 2078-2084.
- Burnett JR, Hooper AJ. 2008. Common and rare gene variants affecting plasma LDL cholesterol. *Clin Biochem. Rev.* 29: 11-26.
- Cao G, Garcia CK, Wyne KL, Schultz RA, Parker KL, Hobbs HH. 1997. Structure and localization of the human gene encoding SR-BI/CLA-1. Evidence for transcriptional control by steroidogenic factor 1. *J. Biol. Chem.* 272: 33068-33076.
- Cavelier C, Rohrer L, von EA. 2006. ATP-Binding cassette transporter A1 modulates apolipoprotein A-I transcytosis through aortic endothelial cells. *Circ. Res.* 99: 1060-1066.
- Chang MH, Yesupriya A, Ned RM, Mueller PW, Dowling NF. 2010. Genetic variants associated with fasting blood lipids in the U.S. population: Third National Health and Nutrition Examination Survey. *BMC. Med. Genet.* 11: 62.
- Chen SN, Ballantyne CM, Gotto AM, Jr., Tan Y, Willerson JT, Marian AJ. 2005. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. *J. Am. Coll. Cardiol.* 45: 1611-1619.
- Clee SM, Zwinderman AH, Engert JC, et al. 2001. Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease. *Circulation* 103: 1198-1205.
- Corella D, Guillen M, Saiz C, Portoles O, Sabater A, Folch J, Ordovas JM. 2002. Associations of LPL and APOC3 gene polymorphisms on plasma lipids in a Mediterranean population: interaction with tobacco smoking and the APOE locus. *J. Lipid Res.* 43: 416-427.

- Costanza MC, Cayanis E, Ross BM, Flaherty MS, Alvin GB, Das K, Morabia A. 2005. Relative contributions of genes, environment, and interactions to blood lipid concentrations in a general adult population. *Am. J. Epidemiol.* 161: 714-724.
- Davignon J, Dubuc G, Seidah NG. 2010. The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis. *Curr. Atheroscler. Rep.* 12: 308-315.
- de Andrade FM, Silveira FR, Arsand M, et al. 2004. Association between -250G/A polymorphism of the hepatic lipase gene promoter and coronary artery disease and HDL-C levels in a Southern Brazilian population. *Clin. Genet.* 65: 390-395.
- Di LE, Magnolo L, Pinotti E, et al. 2009. Functional analysis of two novel splice site mutations of APOB gene in familial hypobetalipoproteinemia. *Mol. Genet. Metab* 96: 66-72.
- Edwards KL, Newman B, Mayer E, Selby JV, Krauss RM, Austin MA. 1997. Heritability of factors of the insulin resistance syndrome in women twins. *Genet. Epidemiol.* 14: 241-253.
- Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. 2002. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. *Am. J. Epidemiol.* 155: 487-495.
- Einhorn D, Reaven GM, Cobin RH, et al. 2003. American College of Endocrinology position statement on the insulin resistance syndrome. *Endocr. Pract.* 9: 237-252.
- Eiriksdottir G, Bolla MK, Thorsson B, Sigurdsson G, Humphries SE, Gudnason V. 2001. The -629C>A polymorphism in the CETP gene does not explain the association of TaqIB polymorphism with risk and age of myocardial infarction in Icelandic men. *Atherosclerosis* 159: 187-192.
- Endo A. 1992. The discovery and development of HMG-CoA reductase inhibitors. *J. Lipid Res.* 33: 1569-1582.
- Evans D, Beil FU. 2006. The E670G SNP in the PCSK9 gene is associated with polygenic hypercholesterolemia in men but not in women. *BMC. Med. Genet.* 7: 66.
- Fang DZ, Liu BW. 2002. Polymorphism of HL +1075C, but not -480T, is associated with plasma high density lipoprotein cholesterol and apolipoprotein AI in men of a Chinese population. *Atherosclerosis* 161: 417-424.
- Ford ES, Giles WH, Dietz WH. 2002. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. *JAMA* 287: 356-359.
- Freeman DJ, Samani NJ, Wilson V, et al. 2003. A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study. *Eur. Heart J.* 24: 1833-1842.
- Frikke-Schmidt R, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. 2004. Genetic variation in ABC transporter A1 contributes to HDL cholesterol in the general population. *J. Clin. Invest* 114: 1343-1353.
- Frikke-Schmidt R, Tybjaerg-Hansen A, Steffensen R, Jensen G, Nordestgaard BG. 2000. Apolipoprotein E genotype: epsilon32 women are protected while epsilon43 and epsilon44 men are susceptible to ischemic heart disease: the Copenhagen City Heart Study. *J. Am. Coll. Cardiol.* 35: 1192-1199.

- Garaulet M, Lee YC, Shen J, Parnell LD, Arnett DK, Tsai MY, Lai CQ, Ordovas JM. 2009. CLOCK genetic variation and metabolic syndrome risk: modulation by monounsaturated fatty acids. *Am. J. Clin Nutr.* 90: 1466-1475.
- Garg A, Simha V. 2007. Update on dyslipidemia. *J. Clin Endocrinol. Metab* 92: 1581-1589.
- Goldberg IJ. 1996. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. *J. Lipid Res.* 37: 693-707.
- Goode EL, Cherny SS, Christian JC, Jarvik GP, de AM. 2007. Heritability of longitudinal measures of body mass index and lipid and lipoprotein levels in aging twins. *Twin. Res. Hum. Genet.* 10: 703-711.
- Graf GA, Yu L, Li WP, Gerard R, Tuma PL, Cohen JC, Hobbs HH. 2003. ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion. *J. Biol. Chem.* 278: 48275-48282.
- Grallert H, Sedlmeier EM, Huth C, Kolz M, Heid IM, Meisinger C, Herder C, Strassburger K, Gehringer A, Haak M, Giani G, Kronenberg F, Wichmann HE, Adamski J, Paulweber B, Illig T, Rathmann W. 2007. APOA5 variants and metabolic syndrome in Caucasians. *J. Lipid Res.* 48: 2614-2621.
- Grarup N, Andreasen CH, Andersen MK, et al. 2008. The -250G>A promoter variant in hepatic lipase associates with elevated fasting serum high-density lipoprotein cholesterol modulated by interaction with physical activity in a study of 16,156 Danish subjects. *J. Clin. Endocrinol. Metab* 93: 2294-2299.
- Gronroos P, Raitakari OT, Kahonen M, et al. 2008. Relation of apolipoprotein E polymorphism to markers of early atherosclerotic changes in young adults--the Cardiovascular Risk in Young Finns Study. *Circ. J.* 72: 29-34.
- Grundey SM, Cleeman JI, Daniels SR, et al. 2006. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. *Curr. Opin. Cardiol.* 21: 1-6.
- Grundey SM, Cleeman JI, Merz CN, et al. 2004. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. *J. Am. Coll. Cardiol.* 44: 720-732.
- Gutierrez-Cirlos C, Ordonez-Sanchez ML, Tusie-Luna MT, Patterson BW, Schonfeld G, Aguilar-Salinas CA. 2011. Familial hypobetalipoproteinemia in a hospital survey: genetics, metabolism and non-alcoholic fatty liver disease. *Ann. Hepatol.* 10: 155-164.
- Haas BE, Weissglas-Volkov D, Aguilar-Salinas CA, et al. 2011. Evidence of how rs7575840 influences apolipoprotein B-containing lipid particles. *Arterioscler. Thromb. Vasc. Biol.* 31: 1201-1207.
- Halpern A, Mancini MC, Magalhaes ME, et al. 2010. Metabolic syndrome, dyslipidemia, hypertension and type 2 diabetes in youth: from diagnosis to treatment. *Diabetol. Metab Syndr.* 2: 55.
- Hegele RA, Brunt JH, Connelly PW. 1995. Multiple genetic determinants of variation of plasma lipoproteins in Alberta Hutterites. *Arterioscler. Thromb. Vasc. Biol.* 15: 861-871.
- Heid IM, Boes E, Muller M, Kollerits B, et al. 2008. Genome-wide association analysis of high-density lipoprotein cholesterol in the population-based KORA study sheds new light on intergenic regions. *Circ. Cardiovasc. Genet.* 1: 10-20.

- Herbeth B, Samara A, Ndiaye C, Marteau JB, Berrahmoune H, Siest G, Visvikis-Siest S. 2010. Metabolic syndrome-related composite factors over 5 years in the STANISLAS family study: genetic heritability and common environmental influences. *Clin Chim. Acta* 411: 833-839.
- Hiura Y, Tabara Y, Kokubo Y, Okamura T, Goto Y, Nonogi H, Miki T, Tomoike H, Iwai N. 2010. Association of the functional variant in the 3-hydroxy-3-methylglutaryl-coenzyme a reductase gene with low-density lipoprotein-cholesterol in Japanese. *Circ. J.* 74: 518-522.
- Hodoglugil U, Williamson DW, Huang Y, Mahley RW. 2005. Common polymorphisms of ATP binding cassette transporter A1, including a functional promoter polymorphism, associated with plasma high density lipoprotein cholesterol levels in Turks. *Atherosclerosis* 183: 199-212.
- Holmer SR, Hengstenberg C, Mayer B, Doring A, Lowel H, Engel S, Hense HW, Wolf M, Klein G, Riegger GA, Schunkert H. 2000. Lipoprotein lipase gene polymorphism, cholesterol subfractions and myocardial infarction in large samples of the general population. *Cardiovasc. Res.* 47: 806-812.
- Hsu LA, Ko YL, Wu S, Teng MS, Peng TY, Chen CF, Chen CF, Lee YS. 2003. Association between a novel 11-base pair deletion mutation in the promoter region of the scavenger receptor class B type I gene and plasma HDL cholesterol levels in Taiwanese Chinese. *Arterioscler. Thromb. Vasc. Biol.* 23: 1869-1874.
- Huang CC, Fornage M, Lloyd-Jones DM, Wei GS, Boerwinkle E, Liu K. 2009. Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study. *Circ. Cardiovasc. Genet.* 2: 354-361.
- Hubacek JA. 2005. Apolipoprotein A5 and triglyceridemia. Focus on the effects of the common variants. *Clin. Chem. Lab Med.* 43: 897-902.
- Hutter CM, Austin MA, Farin FM, Viernes HM, Edwards KL, Leonetti DL, McNeely MJ, Fujimoto WY. 2006. Association of endothelial lipase gene (LIPG) haplotypes with high-density lipoprotein cholesterol subfractions and apolipoprotein AI plasma levels in Japanese Americans. *Atherosclerosis* 185: 78-86.
- Iijima H, Emi M, Wada M, Daimon M, Toriyama S, Koyano S, Sato H, Hopkins PN, Hunt SC, Kubota I, Kawata S, Kato T. 2008. Association of an intronic haplotype of the LIPC gene with hyperalphalipoproteinemia in two independent populations. *J. Hum. Genet.* 53: 193-200.
- Iizuka K, Horikawa Y. 2008. ChREBP: a glucose-activated transcription factor involved in the development of metabolic syndrome. *Endocr. J.* 55: 617-624.
- Isaacs A, Aulchenko YS, Hofman A, et al. 2007. Epistatic effect of cholesteryl ester transfer protein and hepatic lipase on serum high-density lipoprotein cholesterol levels. *J. Clin. Endocrinol. Metab* 92: 2680-2687.
- Jakulj L, Vissers MN, Tanck MW, Hutten BA, Stellaard F, Kastelein JJ, Dallinga-Thie GM. 2010. ABCG5/G8 polymorphisms and markers of cholesterol metabolism: systematic review and meta-analysis. *J. Lipid Res.* 51: 3016-3023.
- Jaye M, Krawiec J. 2004. Endothelial lipase and HDL metabolism. *Curr. Opin. Lipidol.* 15: 183-189.
- Johansen CT, Hegele RA. 2011. Genetic bases of hypertriglyceridemic phenotypes. *Curr. Opin. Lipidol.* 22: 247-253.

- Joy T, Lahiry P, Pollex RL, Hegele RA. 2008. Genetics of metabolic syndrome. *Curr. Diab. Rep.* 8: 141-148.
- Kahn R, Buse J, Ferrannini E, Stern M. 2005. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* 28: 2289-2304.
- Kamboh MI, Bunker CH, Aston CE, Nestlerode CS, McAllister AE, Ukoli FA. 1999a. Genetic association of five apolipoprotein polymorphisms with serum lipoprotein-lipid levels in African blacks. *Genet. Epidemiol.* 16: 205-222.
- Kamboh MI, Manzi S, Mehdi H, Fitzgerald S, Sanghera DK, Kuller LH, Atson CE. 1999b. Genetic variation in apolipoprotein H (beta2-glycoprotein I) affects the occurrence of antiphospholipid antibodies and apolipoprotein H concentrations in systemic lupus erythematosus. *Lupus* 8: 742-750.
- Kataoka S, Robbins DC, Cowan LD, Go O, Yeh JL, Devereux RB, Fabsitz RR, Lee ET, Welty TK, Howard BV. 1996. Apolipoprotein E polymorphism in American Indians and its relation to plasma lipoproteins and diabetes. The Strong Heart Study. *Arterioscler. Thromb. Vasc. Biol.* 16: 918-925.
- Kathiresan S, Melander O, Anevski D, et al. 2008a. Polymorphisms associated with cholesterol and risk of cardiovascular events. *N. Engl. J. Med.* 358: 1240-1249.
- Kathiresan S, Melander O, Guiducci C, et al. 2008b. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. *Nat. Genet.* 40: 189-197.
- Keebler ME, Sanders CL, Surti A, Guiducci C, Burt NP, Kathiresan S. 2009. Association of blood lipids with common DNA sequence variants at 19 genetic loci in the multiethnic United States National Health and Nutrition Examination Survey III. *Circ. Cardiovasc. Genet.* 2: 238-243.
- Klerkx AH, Tanck MW, Kastelein JJ, Molhuizen HO, Jukema JW, Zwinderman AH, Kuivenhoven JA. 2003. Haplotype analysis of the CETP gene: not TaqIB, but the closely linked -629C-->A polymorphism and a novel promoter variant are independently associated with CETP concentration. *Hum. Mol. Genet.* 12: 111-123.
- Klos KL, Kullo IJ. 2007. Genetic determinants of HDL: monogenic disorders and contributions to variation. *Curr. Opin. Cardiol.* 22: 344-351.
- Klos KL, Sing CF, Boerwinkle E, Hamon SC, Rea TJ, Clark A, Fornage M, Hixson JE. 2006. Consistent effects of genes involved in reverse cholesterol transport on plasma lipid and apolipoprotein levels in CARDIA participants. *Arterioscler. Thromb. Vasc. Biol.* 26: 1828-1836.
- Ko YL, Hsu LA, Hsu KH, Ko YH, Lee YS. 2004. The interactive effects of hepatic lipase gene promoter polymorphisms with sex and obesity on high-density-lipoprotein cholesterol levels in Taiwanese-Chinese. *Atherosclerosis* 172: 135-142.
- Komurcu-Bayrak E, Onat A, Poda M, Humphries SE, Acharya J, Hergenc G, Coban N, Can G, Erginel-Unaltuna N. 2007. The S447X variant of lipoprotein lipase gene is associated with metabolic syndrome and lipid levels among Turks. *Clin. Chim. Acta* 383: 110-115.
- Kretowski A, Hokanson JE, McFann K, Kinney GL, Snell-Bergeon JK, Maahs DM, Wadwa RP, Eckel RH, Ogden LG, Garg SK, Li J, Cheng S, Erlich HA, Rewers M. 2006. The apolipoprotein A-IV Gln360His polymorphism predicts progression of coronary artery calcification in patients with type 1 diabetes. *Diabetologia* 49: 1946-1954.

- Kronenberg F, Coon H, Ellison RC, Borecki I, Arnett DK, Province MA, Eckfeldt JH, Hopkins PN, Hunt SC. 2002. Segregation analysis of HDL cholesterol in the NHLBI Family Heart Study and in Utah pedigrees. *Eur. J. Hum. Genet.* 10: 367-374.
- Kruit JK, Brunham LR, Verchere CB, Hayden MR. 2010. HDL and LDL cholesterol significantly influence beta-cell function in type 2 diabetes mellitus. *Curr. Opin. Lipidol.* 21: 178-185.
- Kwan BC, Kronenberg F, Beddhu S, Cheung AK. 2007. Lipoprotein metabolism and lipid management in chronic kidney disease. *J. Am. Soc. Nephrol.* 18: 1246-1261.
- Lahiry P, Ban MR, Pollex RL, et al. 2007. Common variants APOC3, APOA5, APOE and PON1 are associated with variation in plasma lipoprotein traits in Greenlanders. *Int. J. Circumpolar. Health* 66: 390-400.
- Lai CQ, Tai ES, Tan CE, Cutter J, Chew SK, Zhu YP, Adiconis X, Ordovas JM. 2003. The APOA5 locus is a strong determinant of plasma triglyceride concentrations across ethnic groups in Singapore. *J. Lipid Res.* 44: 2365-2373.
- Lamarche B, Paradis ME. 2007. Endothelial lipase and the metabolic syndrome. *Curr. Opin. Lipidol.* 18: 298-303.
- Lanktree MB, Anand SS, Yusuf S, Hegele RA. 2009. Replication of genetic associations with plasma lipoprotein traits in a multiethnic sample. *J. Lipid Res.* 50: 1487-1496.
- Larson IA, Ordovas JM, Barnard JR, Hoffmann MM, Feussner G, Lamon-Fava S, Schaefer EJ. 2002. Effects of apolipoprotein A-I genetic variations on plasma apolipoprotein, serum lipoprotein and glucose levels. *Clin Genet.* 61: 176-184.
- Lee J, Tan CS, Chia KS, Tan CE, Chew SK, Ordovas JM, Tai ES. 2004. The lipoprotein lipase S447X polymorphism and plasma lipids: interactions with APOE polymorphisms, smoking, and alcohol consumption. *J. Lipid Res.* 45: 1132-1139.
- Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R. 2007. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. *Lancet* 370: 1829-1839.
- Lewis GF, Rader DJ. 2005. New insights into the regulation of HDL metabolism and reverse cholesterol transport. *Circ. Res.* 96: 1221-1232.
- Lin HF, Boden-Albala B, Juo SH, Park N, Rundek T, Sacco RL. 2005. Heritabilities of the metabolic syndrome and its components in the Northern Manhattan Family Study. *Diabetologia* 48: 2006-2012.
- Linsel-Nitschke P, Tall AR. 2005. HDL as a target in the treatment of atherosclerotic cardiovascular disease. *Nat. Rev. Drug Discov.* 4: 193-205.
- Littlewood TD, Bennett MR. 2003. Apoptotic cell death in atherosclerosis. *Curr. Opin. Lipidol.* 14: 469-475.
- Lusis AJ, Attie AD, Reue K. 2008. Metabolic syndrome: from epidemiology to systems biology. *Nat. Rev. Genet.* 9: 819-830.
- Ma K, Cilingiroglu M, Otvos JD, Ballantyne CM, Marian AJ, Chan L. 2003. Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. *Proc. Natl. Acad. Sci. U. S. A* 100: 2748-2753.
- Mackness MI, Arrol S, Durrington PN. 1991. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. *FEBS Lett.* 286: 152-154.


- Maily F, Tugrul Y, Reymer PW, et al. 1995. A common variant in the gene for lipoprotein lipase (Asp9-->Asn). Functional implications and prevalence in normal and hyperlipidemic subjects. *Arterioscler. Thromb. Vasc. Biol.* 15: 468-478.
- Mank-Seymour AR, Durham KL, Thompson JF, Seymour AB, Milos PM. 2004. Association between single-nucleotide polymorphisms in the endothelial lipase (LIPG) gene and high-density lipoprotein cholesterol levels. *Biochim. Biophys. Acta* 1636: 40-46.
- Manresa JM, Zamora A, Tomas M, et al. 2006. Relationship of classical and non-classical risk factors with genetic variants relevant to coronary heart disease. *Eur. J. Cardiovasc. Prev. Rehabil.* 13: 738-744.
- Maxwell KN, Fisher EA, Breslow JL. 2005. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. *Proc. Natl. Acad. Sci. U. S. A* 102: 2069-2074.
- McCaskie PA, Cadby G, Hung J, McQuillan BM, Chapman CM, Carter KW, Thompson PL, Palmer LJ, Beilby JP. 2006. The C-480T hepatic lipase polymorphism is associated with HDL-C but not with risk of coronary heart disease. *Clin. Genet.* 70: 114-121.
- Miettinen HE, Gylling H, Tenhunen J, et al. 1998. Molecular genetic study of Finns with hypoalphalipoproteinemia and hyperalphalipoproteinemia: a novel Gly230 Arg mutation (LCAT[Fin]) of lecithin:cholesterol acyltransferase (LCAT) accounts for 5% of cases with very low serum HDL cholesterol levels. *Arterioscler. Thromb. Vasc. Biol.* 18: 591-598.
- Miller M, Rhyne J, Chen H, Beach V, Ericson R, Luthra K, Dwivedi M, Misra A. 2007. APOC3 promoter polymorphisms C-482T and T-455C are associated with the metabolic syndrome. *Arch. Med. Res.* 38: 444-451.
- Miller M, Rhyne J, Hamlette S, Birnbaum J, Rodriguez A. 2003. Genetics of HDL regulation in humans. *Curr. Opin. Lipidol.* 14: 273-279.
- Miller M, Zhan M. 2004. Genetic determinants of low high-density lipoprotein cholesterol. *Curr. Opin. Cardiol.* 19: 380-384.
- Monda KL, North KE, Hunt SC, Rao DC, Province MA, Kraja AT. 2010. The genetics of obesity and the metabolic syndrome. *Endocr. Metab. Immune. Disord. Drug Targets.* 10: 86-108.
- Morabia A, Ross BM, Costanza MC, Cayanis E, Flaherty MS, Alvin GB, Das K, James R, Yang AS, Evagrafov O, Gilliam TC. 2004. Population-based study of SR-BI genetic variation and lipid profile. *Atherosclerosis* 175: 159-168.
- Murthy V, Julien P, Gagne C. 1996. Molecular pathobiology of the human lipoprotein lipase gene. *Pharmacol Ther.* 70: 101-135.
- Musunuru K, Pirruccello JP, Do R, et al. 2010. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. *N. Engl. J. Med.* 363: 2220-2227.
- Nettleton JA, Steffen LM, Ballantyne CM, Boerwinkle E, Folsom AR. 2007. Associations between HDL-cholesterol and polymorphisms in hepatic lipase and lipoprotein lipase genes are modified by dietary fat intake in African American and White adults. *Atherosclerosis* 194: e131-e140.
- Nock NL, Li L, Larkin EK, Patel SR, Redline S. 2009a. Empirical evidence for "syndrome Z": a hierarchical 5-factor model of the metabolic syndrome incorporating sleep disturbance measures. *Sleep* 32: 615-622.

- Nock NL, Wang X, Thompson CL, Song Y, Baechle D, Raska P, Stein CM, Gray-McGuire C. 2009b. Defining genetic determinants of the Metabolic Syndrome in the Framingham Heart Study using association and structural equation modeling methods. *BMC. Proc.* 3 Suppl 7: S50.
- Ordovas JM, Shen J. 2008. Gene-environment interactions and susceptibility to metabolic syndrome and other chronic diseases. *J. Periodontol.* 79: 1508-1513.
- Osgood D, Corella D, Demissie S, et al. 2003. Genetic variation at the scavenger receptor class B type I gene locus determines plasma lipoprotein concentrations and particle size and interacts with type 2 diabetes: the framingham study. *J. Clin Endocrinol. Metab* 88: 2869-2879.
- Ota VK, Chen ES, Ejchel TF, Furuya TK, Mazzotti DR, Cendoroglo MS, Ramos LR, Araujo LQ, Burbano RR, Smith MD. 2011. APOA4 Polymorphism as a Risk Factor for Unfavorable Lipid Serum Profile and Depression: A Cross-Sectional Study. *J. Investig. Med.*
- Pallaud C, Sass C, Zannad F, Siest G, Visvikis S. 2001. APOC3, CETP, fibrinogen, and MTHFR are genetic determinants of carotid intima-media thickness in healthy men (the Stanislas cohort). *Clin Genet.* 59: 316-324.
- Paradis ME, Couture P, Bosse Y, Despres JP, Perusse L, Bouchard C, Vohl MC, Lamarche B. 2003. The T111I mutation in the EL gene modulates the impact of dietary fat on the HDL profile in women. *J. Lipid Res.* 44: 1902-1908.
- Pare G, Serre D, Brisson D, Anand SS, Montpetit A, Tremblay G, Engert JC, Hudson TJ, Gaudet D. 2007. Genetic analysis of 103 candidate genes for coronary artery disease and associated phenotypes in a founder population reveals a new association between endothelin-1 and high-density lipoprotein cholesterol. *Am. J. Hum. Genet.* 80: 673-682.
- Phillips CM, Tierney AC, Roche HM. 2008. Gene-nutrient interactions in the metabolic syndrome. *J. Nutrigenet. Nutrigenomics.* 1: 136-151.
- Polisecki E, Muallem H, Maeda N, et al. 2008. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. *Atherosclerosis* 200: 109-114.
- Pollex RL, Hanley AJ, Zinman B, Harris SB, Khan HM, Hegele RA. 2006. Metabolic syndrome in aboriginal Canadians: prevalence and genetic associations. *Atherosclerosis* 184: 121-129.
- Pollex RL, Hegele RA. 2006. Genetic determinants of the metabolic syndrome. *Nat. Clin Pract. Cardiovasc. Med.* 3: 482-489.
- Porchay I, Pean F, Bellili N, et al. 2006. ABCA1 single nucleotide polymorphisms on high-density lipoprotein-cholesterol and overweight: the D.E.S.I.R. study. *Obesity. (Silver. Spring)* 14: 1874-1879.
- Qi L, Liu S, Rifai N, Hunter D, Hu FB. 2007. Associations of the apolipoprotein A1/C3/A4/A5 gene cluster with triglyceride and HDL cholesterol levels in women with type 2 diabetes. *Atherosclerosis* 192: 204-210.
- Remaley AT, Stonik JA, Demosky SJ, et al. 2001. Apolipoprotein specificity for lipid efflux by the human ABCA1 transporter. *Biochem. Biophys. Res. Commun.* 280: 818-823.
- Rigotti A, Trigatti B, Babitt J, Penman M, Xu S, Krieger M. 1997. Scavenger receptor BI--a cell surface receptor for high density lipoprotein. *Curr. Opin. Lipidol.* 8: 181-188.

- Rios DL, D'Onofrio LO, Cerqueira CC, et al. 2007. Paraoxonase 1 gene polymorphisms in angiographically assessed coronary artery disease: evidence for gender interaction among Brazilians. *Clin. Chem. Lab Med.* 45: 874-878.
- Rip J, Nierman MC, Ross CJ, Jukema JW, Hayden MR, Kastelein JJ, Stroes ES, Kuivenhoven JA. 2006. Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation. *Arterioscler. Thromb. Vasc. Biol.* 26: 1236-1245.
- Roberts CG, Shen H, Mitchell BD, Damcott CM, Shuldiner AR, Rodriguez A. 2007. Variants in scavenger receptor class B type I gene are associated with HDL cholesterol levels in younger women. *Hum. Hered.* 64: 107-113.
- Roth GA, Fihn SD, Mokdad AH. 2010. High total serum cholesterol, medication coverage and therapeutic control: an analysis of national health examination survey data from eight countries. In: pp. 92-101.
- Russo GT, Meigs JB, Cupples LA, et al. 2001. Association of the Sst-I polymorphism at the APOC3 gene locus with variations in lipid levels, lipoprotein subclass profiles and coronary heart disease risk: the Framingham offspring study. *Atherosclerosis* 158: 173-181.
- Sagoo GS, Tatt I, Salanti G, Butterworth AS, Sarwar N, van MM, Jukema JW, Wiman B, Kastelein JJ, Bennet AM, de FU, Danesh J, Higgins JP. 2008. Seven lipoprotein lipase gene polymorphisms, lipid fractions, and coronary disease: a HuGE association review and meta-analysis. *Am. J. Epidemiol.* 168: 1233-1246.
- Senti M, Elosua R, Tomas M, Sala J, Masia R, Ordovas JM, Shen H, Marrugat J. 2001. Physical activity modulates the combined effect of a common variant of the lipoprotein lipase gene and smoking on serum triglyceride levels and high-density lipoprotein cholesterol in men. *Hum. Genet.* 109: 385-392.
- Shan L, Yu XC, Liu Z, Hu Y, Sturgis LT, Miranda ML, Liu Q. 2009. The angiopoietin-like proteins ANGPTL3 and ANGPTL4 inhibit lipoprotein lipase activity through distinct mechanisms. *J. Biol. Chem.* 284: 1419-1424.
- Sharma V, McNeill JH. 2006. The etiology of hypertension in the metabolic syndrome part one: an introduction to the history, the concept and the models. *Curr. Vasc. Pharmacol* 4: 293-304.
- Shimizu-gawa T, Ono M, Shimamura M, Yoshida K, Ando Y, Koishi R, Ueda K, Inaba T, Minekura H, Kohama T, Furukawa H. 2002. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. *J. Biol. Chem.* 277: 33742-33748.
- Shioji K, Mannami T, Kokubo Y, Goto Y, Nonogi H, Iwai N. 2004a. An association analysis between ApoA1 polymorphisms and the high-density lipoprotein (HDL) cholesterol level and myocardial infarction (MI) in Japanese. *J. Hum. Genet.* 49: 433-439.
- Shioji K, Nishioka J, Naraba H, et al. 2004b. A promoter variant of the ATP-binding cassette transporter A1 gene alters the HDL cholesterol level in the general Japanese population. *J. Hum. Genet.* 49: 141-147.
- Sookoian S, Pirola CJ. 2011. Metabolic syndrome: from the genetics to the pathophysiology. *Curr. Hypertens. Rep.* 13: 149-157.
- Srinivasan SR, Ehnholm C, Elkasabany A, Berenson G. 1999. Influence of apolipoprotein E polymorphism on serum lipids and lipoprotein changes from childhood to adulthood: the Bogalusa Heart Study. *Atherosclerosis* 143: 435-443.

- Sung J, Lee K, Song YM. 2009. Heritabilities of the metabolic syndrome phenotypes and related factors in Korean twins. *J. Clin Endocrinol. Metab* 94: 4946-4952.
- Sviridov D, Nestel PJ. 2007. Genetic factors affecting HDL levels, structure, metabolism and function. *Curr. Opin. Lipidol.* 18: 157-163.
- Tai ES, Corella D, Deurenberg-Yap M, Cutter J, Chew SK, Tan CE, Ordovas JM. 2003a. Dietary fat interacts with the -514C>T polymorphism in the hepatic lipase gene promoter on plasma lipid profiles in a multiethnic Asian population: the 1998 Singapore National Health Survey. *J. Nutr.* 133: 3399-3408.
- Tai ES, Ordovas JM, Corella D, Deurenberg-Yap M, Chan E, Adiconis X, Chew SK, Loh LM, Tan CE. 2003b. The TaqIB and -629C>A polymorphisms at the cholesteryl ester transfer protein locus: associations with lipid levels in a multiethnic population. The 1998 Singapore National Health Survey. *Clin. Genet.* 63: 19-30.
- Talmud PJ, Hawe E, Martin S, Olivier M, Miller GJ, Rubin EM, Pennacchio LA, Humphries SE. 2002a. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. *Hum. Mol. Genet.* 11: 3039-3046.
- Talmud PJ, Hawe E, Robertson K, Miller GJ, Miller NE, Humphries SE. 2002b. Genetic and environmental determinants of plasma high density lipoprotein cholesterol and apolipoprotein AI concentrations in healthy middle-aged men. *Ann. Hum. Genet.* 66: 111-124.
- Tang NP, Wang LS, Yang L, Zhou B, Gu HJ, Sun QM, Cong RH, Zhu HJ, Wang B. 2008. Protective effect of an endothelial lipase gene variant on coronary artery disease in a Chinese population. *J. Lipid Res.* 49: 369-375.
- Teslovich TM, Musunuru K, Smith AV, Edmondson AC, et al. 2010. Biological, clinical and population relevance of 95 loci for blood lipids. *Nature* 466: 707-713.
- Thompson A, Di AE, Sarwar N, Erqou S, Saleheen D, Dullaart RP, Keavney B, Ye Z, Danesh J. 2008. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. *JAMA* 299: 2777-2788.
- van Aalst-Cohen ES, Jansen AC, Boekholdt SM, Tanck MW, Fontecha MR, Cheng S, Li J, Defesche JC, Kuivenhoven JA, Kastelein JJ. 2005. Genetic determinants of plasma HDL-cholesterol levels in familial hypercholesterolemia. *Eur. J. Hum. Genet.* 13: 1137-1142.
- Volcik KA, Barkley RA, Hutchinson RG, Mosley TH, Heiss G, Sharrett AR, Ballantyne CM, Boerwinkle E. 2006. Apolipoprotein E polymorphisms predict low density lipoprotein cholesterol levels and carotid artery wall thickness but not incident coronary heart disease in 12,491 ARIC study participants. *Am. J. Epidemiol.* 164: 342-348.
- Wang J, Ban MR, Zou GY, Cao H, Lin T, Kennedy BA, Anand S, Yusuf S, Huff MW, Pollex RL, Hegele RA. 2008. Polygenic determinants of severe hypertriglyceridemia. *Hum. Mol. Genet.* 17: 2894-2899.
- Wang X, Paigen B. 2005. Genetics of variation in HDL cholesterol in humans and mice. *Circ. Res.* 96: 27-42.
- Waterworth DM, Ricketts SL, Song K, et al. 2010. Genetic variants influencing circulating lipid levels and risk of coronary artery disease. *Arterioscler. Thromb. Vasc. Biol.* 30: 2264-2276.

- Whiting BM, Anderson JL, Muhlestein JB, Horne BD, Bair TL, Pearson RR, Carlquist JF. 2005. Candidate gene susceptibility variants predict intermediate end points but not angiographic coronary artery disease. *Am. Heart J.* 150: 243-250.
- Willer CJ, Sanna S, Jackson AU, et al. 2008. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. *Nat. Genet.* 40: 161-169.
- Wilson PW, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. 1994. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. *JAMA* 272: 1666-1671.
- Wittrup HH, Tybjaerg-Hansen A, Nordestgaard BG. 1999. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. *Circulation* 99: 2901-2907.
- Wu K, Bowman R, Welch AA, Luben RN, Wareham N, Khaw KT, Bingham SA. 2007. Apolipoprotein E polymorphisms, dietary fat and fibre, and serum lipids: the EPIC Norfolk study. *Eur. Heart J.* 28: 2930-2936.
- Yamada Y, Ichihara S, Kato K, et al. 2008. Genetic risk for metabolic syndrome: examination of candidate gene polymorphisms related to lipid metabolism in Japanese people. *J. Med. Genet.* 45: 22-28.
- Yamada Y, Matsuo H, Warita S, et al. 2007. Prediction of genetic risk for dyslipidemia. *Genomics* 90: 551-558.
- Yamakawa-Kobayashi K, Yanagi H, Endo K, Arinami T, Hamaguchi H. 2003. Relationship between serum HDL-C levels and common genetic variants of the endothelial lipase gene in Japanese school-aged children. *Hum. Genet.* 113: 311-315.
- Zhang K, Zhang S, Zheng K, Hou Y, Liao L, He Y, Zhang L, Nebert DW, Shi J, Su Z, Xiao C. 2004. Novel P143L polymorphism of the LCAT gene is associated with dyslipidemia in Chinese patients who have coronary atherosclerotic heart disease. *Biochem. Biophys. Res. Commun.* 318: 4-10.
- Zhu XY, Xu HW, Hou RY, Liu HF, Xiao B, Yang XS, Yang QD, Tang BS. 2006. [Lecithin-cholesterol acyltransferase gene 608C/T polymorphism associated with atherosclerotic cerebral infarction]. *Zhonghua Yi. Xue. Yi. Chuan Xue. Za Zhi.* 23: 419-422.



Dyslipidemia - From Prevention to Treatment

Edited by Prof. Roya Kelishadi

ISBN 978-953-307-904-2

Hard cover, 468 pages

Publisher InTech

Published online 03, February, 2012

Published in print edition February, 2012

Dyslipidemia has a complex pathophysiology consisting of various genetic, lifestyle, and environmental factors. It has many adverse health impacts, notably in the development of chronic non-communicable diseases. Significant ethnic differences exist due to the prevalence and types of lipid disorders. While elevated serum total- and LDL-cholesterol are the main concern in Western populations, in other countries hypertriglyceridemia and low HDL-cholesterol are more prevalent. The latter types of lipid disorders are considered as components of the metabolic syndrome. The escalating trend of obesity, as well as changes in lifestyle and environmental factors will make dyslipidemia a global medical and public health threat, not only for adults but for the pediatric age group as well. Several experimental and clinical studies are still being conducted regarding the underlying mechanisms and treatment of dyslipidemia. The current book is providing a general overview of dyslipidemia from diverse aspects of pathophysiology, ethnic differences, prevention, health hazards, and treatment.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Nora L. Nock and Aiswarya L.P. Chandran Pillai (2012). Dyslipidemia: Genetics and Role in the Metabolic Syndrome, *Dyslipidemia - From Prevention to Treatment*, Prof. Roya Kelishadi (Ed.), ISBN: 978-953-307-904-2, InTech, Available from: <http://www.intechopen.com/books/dyslipidemia-from-prevention-to-treatment/dyslipidemia-genetics-and-role-in-the-metabolic-syndrome>

INTECH

open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.